EP2456423A2 - Traitement de troubles hyperprolifératifs - Google Patents

Traitement de troubles hyperprolifératifs

Info

Publication number
EP2456423A2
EP2456423A2 EP10734023A EP10734023A EP2456423A2 EP 2456423 A2 EP2456423 A2 EP 2456423A2 EP 10734023 A EP10734023 A EP 10734023A EP 10734023 A EP10734023 A EP 10734023A EP 2456423 A2 EP2456423 A2 EP 2456423A2
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
alkyl
pharmaceutical
group
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10734023A
Other languages
German (de)
English (en)
Inventor
Bjarne Bymose
Elisabeth DE DARKÓ
Jørgen HYLDGAARD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valderm ApS
Original Assignee
Valderm ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valderm ApS filed Critical Valderm ApS
Publication of EP2456423A2 publication Critical patent/EP2456423A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Definitions

  • the present invention relates to stable pharmaceutical formulations comprising a solubilized lipophilic anthracycline and the uses thereof in the treatment of clinical conditions, wherein hyperproliferation, preferably epithelial hyperproliferation, and more preferably hyperproliferating keratinocytes is a primary factor of the pathogenesis.
  • Anthracyclines are antibiotics having potent antineoplastic activity, and accordingly they have been used in the treatment of a variety of cancers. Anthracyclines are amongst the most utilised antitumor drugs ever developed. Anthracyclines mediate their anticancer effect in part by targeting topisomerase II, which leads to DNA damage. Anthracyclines are essential components of several curative drug
  • anthracyclines for example comprises doxorubicin, valrubicin, epirubicin, daunorubicin and idarubicin.
  • Doxorubicin, daunorubicin, idarubicin and epirubicin are usually administered systemically by intravenous injection or infusion. Systemic administration of these anthracyclines, however, results in a number of undesirable side effects such as cardiotoxicity and bone marrow suppression.
  • Anthracyclines are in general known to be very tissue toxic. For example, paravenous extravasation of doxorubicin results in severe necrosis and immediate measures have to be undertaken to avoid severe local toxicity. It is also known that several others are in general known to be very tissue toxic. For example, paravenous extravasation of doxorubicin results in severe necrosis and immediate measures have to be undertaken to avoid severe local toxicity. It is also known that several others are in general known to be very tissue toxic. For example, paravenous extravasation of doxorubi
  • Valrubicin is a semisynthetic analogue of doxorubicin and it is developed for the treatment of superficial bladder cancer and approved for such use in the United States. Usually a total of 800 mg is administered by intravesical instillation of two hours +- duration for a total of 6 times once a week. (FDA. ValstarTM (Valrubicin) Sterile
  • the approved formulation contains 40 mg/ml Valrubicin in 50%
  • CremephorOEL polyoxyl castor oil
  • 50% dehydrated alcohol USP 50% dehydrated alcohol USP. Unopened vials of VALSTARTM are stable until the date indicated on the package when stored under refrigerated conditions at 2°-8°C (36°-46°F). Vials should not be heated.
  • VALSTARTM diluted in 0.9% Sodium Chloride Injection USP for administration is stable for 12 hours at temperatures up to 25°C (77°F).
  • hyperproliferation defined as an abnormal high rate of cell division, is a primary factor of pathogenesis.
  • Psoriasis is a chronic disease characterised by epidermal hyperproliferation, abnormal cell differentiation with reduced programmed cell death (apoptosis) and parakeratosis, inflammatory infiltration of epidermis and dermis with vascular dilatation resulting in clinical symptoms such as increased thickness of the skin, erythema and scaling
  • Treatment of psoriasis depends on a number of factors such as the severity of the disease, the type of psoriasis, the body region involved, responsiveness to former treatments, the age and sex of the patient and the patient motivation.
  • Management of psoriasis comprises a large repertoire of topical or systemic treatments and photo(chemo)therapy. Within recent years biological therapies have provided additional opportunities for systemic treatments.
  • the mainstay in treatment of psoriasis is topical treatment.
  • the majority of patients (two of three patients) suffer from mild to moderate psoriasis and will benefit from topical treatment as single therapy or in conjunction with other therapies.
  • First line therapy is topical treatment with vitamin D-analogues or corticosteroids.
  • Vitamin- D analogues have an antiproliferative effect and stimulate cell differentiation although they have a slower onset of action than steroids. Side effects such as burning sensation, itching and erythema are common (1-10%)
  • Corticosteroids have an anti-inflammatory effect and a fast onset of action.
  • Common side effects of steroids include thinning of the skin burning sensation and itching.
  • repeat administration of steroids may result in tachyphylaxis or rebound phenomena.
  • Coal tar ointment or coal tar baths which have an anti-inflammatory and antiproliferative effect. Common side effects are skin irritation and staining of clothes in addition to allergic and phototoxic responses.
  • Topical synthetic retinoids like e.g. Tazarotene, which is available in limitied territories only. Tazarotene has anti-inflammatory and antiproliferative effects. Common side effects are erythema, pruritus and scaling of the skin including surrounding normal skin. Retinoids have a known teratogenicity potential.
  • Topical calcineurin inhibitors such as Tacrolimus and Pimecrolimus which are macrolide immunosuppressants and inhibit T-cell activation.
  • neoplastic and preneoplastic conditions Other clinical conditions wherein hyperproliferation is a primary factor of pathogenesis include neoplastic and preneoplastic conditions. For many of these diseases no effective local treatment can be offered apart from surgery. In particular, neoplastic and preneoplastic conditions of the genitals, reproductive organs, gastrointestinal tract and upper airway tract, lips, oral cavity and nasal cavity are generally treated by surgery.
  • anthracyclines can be used in the treatment of clinical conditions of body surfaces such as skin and mucosal membranes, wherein abnormal cell differentiation and/or hyperproliferation is a primary factor of the pathogenesis.
  • the treatment of psoriasis by topical administration of valrubicin comprised in a liquid formulation is disclosed.
  • this document is neither concerned with stability of the liquid formulations nor with ability of the anthracyclines to reach target cells.
  • the present invention relates to novel formulations comprising lipophilic anthracyclines that can advantageously be used in local treatment of psoriasis and other clinical conditions, wherein hyperproliferation, such as epithelial hyperproliferation
  • the novel formulations according to the present invention provide a very good penetration of the lipophilic anthracyclines through tissue surfaces, such as through the epithelium of epidermis and through mucosal epithelial membranes and thereby a greater part of the anthracycline reaches the cell layers, in which the hyperproliferative target cells are located.
  • the formulations according to the present invention show excellent release and penetration efficiency as compared to formulations known in the art.
  • composition further comprises an aqueous phase comprising at least one buffering system having a pH from about pH 2.2 to about pH 6, and wherein the water content of the pharmaceutical composition is less than 30%.
  • the present invention provides methods of treatment of a condition associated with hyperproliferation, preferably epithelial hyperproliferation, more preferably epidermal hyperproliferation in an individual in need thereof comprising administering topically to said individual a pharmaceutical composition comprising i) a lipophilic anthracycline;
  • composition further comprises an aqueous phase comprising at least one buffering system having a pH from about pH 2.2 to about pH 6, preferably from pH 2.2 to pH 5.0, and wherein the water content of the pharmaceutical composition is less than 30%.
  • compositions comprising a lipophilic anthracycline formulated for local administration for the preparation of a medicament for the treatment of a neoplastic or preneoplastic condition affecting the epithelium of genitals, reproductive organs, nasal cavity, lips, pharynx, larynx or affecting the eye. It is a further object of the present invention to provide pharmaceutical compositions comprising a lipophilic anthracycline, wherein the composition comprises an aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 6.0.
  • Figure 1A shows the dose response effect expressed as % proliferation of DJM-1 cells upon application of increasing amount of compounds. From left to right: Valrubicin 24 h; Valrubicin 48 h; AD41 24 h; AD41 48 h; Doxorubicin 24 hr; Doxorubicin 48 hr.
  • Figure 1 B shows the dose response effect expressed as % proliferation of HSC-1 cells upon application of increasing amount of compounds. From left to right: Valrubicin 24 h; Valrubicin 48 h; AD41 24 h; AD41 48 h; Doxorubicin 24 hr; Doxorubicin 48 hr.
  • Figure 1 C shows the dose response effect expressed as % proliferation of HaCaT cells upon application of increasing amount of compounds. From left to right: Valrubicin 24 h; Valrubicin 48 h; AD41 24 h; AD41 48 h; Doxorubicin 24 hr; Doxorubicin 48 hr.
  • Figure 2 shows the effect of Valrubicin investigated in three distinct cultures of primary keratinocytes. Proliferation curves are shown at 48 hours.
  • Figure 3A-C shows the effect of valrubicin on progression and treatment of skin cancer in mice in vivo. The skin cancer is induced by DMBA/TPA.
  • Figure 3C shows tumour volumes in the three groups as measured in mm 3 .
  • Figure 4A-E shows the semi quantitative clinical psoriasis score in HuSCID mice engrafted with human psoriasis plague skin and either untreated (diamonds), treated with vehicle (VLD32 without valrubicin - small squares), treated with valrubicin (VLD32 - triangles), treated with Calcipotriol - large squares) or Bethametasone valerate - medium squares).
  • Fig. 4A-E represents 5 different series using psoriasis plaque skin from 5 different donors.
  • Figure 5A-I shows the dose-response anti-proliferative effect of valrubicin and doxorubicin expressed as percentage reduction of cell viability of the human SCC cell lines, CaSki (cervix HPV16) (Figs. 5A-C), SW756 (cervix HPV18)(Figs. 5D-F) and CW954 (vulva)(Figs. 5G-I) upon stimulation with compounds for 24-, 48- and 72 hrs. Proliferation curves are shown at 24, 48 and 72 hrs with percentage reduction of cell viability (100% as reference value) at different concentration of compounds applied.
  • Figure 6 shows a comparison of Valrubicin amount [ ⁇ g/cm 2 ] found in the 2 first tape- strips (2TS), 16 tape-strips (Stratum Corneum, 16TS), deeper skin layers (residual skin after stripping) and acceptor medium after 24 hrs exposure of normal skin to the formulations A (JH32) and VDL32.
  • Figure 7 shows a comparison of Valrubicin amount [ ⁇ g/cm 2 ] found in the 2 first tape- strips (2TS), 6 tape-strips (Residual Stratum Corneum, 6TS), deeper skin layers (residual skin after stripping) and acceptor medium after 24 hrs exposure of abraded skin to the formulation A (JH32) and VDL32.
  • Figure 8 shows the penetration of Valrubicin into cervical tissue after 24-hour incubation with emulsified gel 4, valrubicin 1%.
  • Figure 9 shows the penetration of Valrubicin into cervical tissue after 24-hour incubation with emulsified 4 gel valrubicin 1 %.
  • the diagram shows the concentration profile in the tissue from donor 2.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising
  • composition further comprises an aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 6.
  • the anthracyclines of the present invention are in general lipophilic anthracyclines, in particular such lipophilic anthracyclines, which are capable of passing the cell membrane and enter the cytoplasm of cells in a fast manner.
  • the lipophilic anthracyclines according to the invention do not enter nucleus of cells to any significant degree.
  • the lipophilic anthracyclines may in some instances be characterised by their partition coefficient (P) and log P.
  • the partition coefficient is the ratio of a given compound partitioned between two solvents, traditionally the solvent system is octanol/water.
  • the log P oc ta n oi can be measured in a range from -2 to 6, and compounds having a log P O ctanoi/water of about 0,5 to about 2 may be considered moderately lipophilic, compounds having a log P O ctanoi/water above 2 may be considered increasingly lipophilic.
  • lipophilic anthracyclines according to the present invention may preferably have a log P oc tanoi/water value greater than 0.5, preferably greater than 1.0, more preferably greater than 1.5, even more preferably greater than 2.0, yet even more preferably greater than 3.0.
  • the pH may have an influence on the determination of the partition coefficient, due to possible ionization of the compound in question, it may be preferred to determine the value at a fixed pH.
  • a buffer system such as e.g. PBS (wherein PBS is phosphate buffered saline, preferably 0.01 M phosphate in 8.5% NaCI, pH 7.2.).
  • PBS phosphate buffered saline, preferably 0.01 M phosphate in 8.5% NaCI, pH 7.2.
  • the lipophilicity is characterised by the partition coefficient (P) where anthracycline preferably have an octa no I/buffer partition coefficient (such as e.g.
  • octanol PBS partition coefficient greater than 40, more preferably greater than 60, even more preferably greater than 80, and yet even more preferably greater than 100.
  • One useful method for determining the octanol/buffer partition coefficient is described in Panayiotis et al., 1989, Chemistry and Physics of Lipids, 51 :105-1 18.
  • Preferred lipophilic anthracyclines which can be used in the present invention, may have the general formula (I)
  • R 1 is selected from the group consisting of -C(O)CH 2 -O-(Ci-C 6 -acyl), - C(O)CH 2 -O-(Ci-C 6 -alkyl), -C(O)CH 2 -O-(C r C 6 -alkoxy), and -C(O)CH 2 -O-(C r C 6 -acyl)- (Ci-C 6 -alkoxy); and
  • R 2 is selected from the group consisting of -NH-(CrC 6 -acyl), -NH-(CrC 6 -alkyl), -NH- (d-C ⁇ -alkoxy), -N(Ci-C 6 -acyl)(Ci-C 6 -acyl), -N(Ci-C 6 -acyl)(Ci-C 6 -alkyl), -N(C r C 6 -acyl) (d-Ce-alkoxy), -N(Ci-C 6 -alkyl)(Ci-C 6 -alkyl), -N(Ci-C 6 -alkyl)(Ci-C 6 -alkoxy), -N(CrC 6 - alkoxy)(Ci-C 6 -alkoxy), -heterocyclyl, -C(O)CH 2 -O-(CrC 6 -alkyl), -(C r C 6 -acyl),
  • the lipophilic anthracycline is a compound of the general formula (I).
  • Ri may preferably be -C(O)CH 2 -O-(CrC 6 - acyl); and more preferably Ri may be -COCH2 ⁇ CO(CH2)3CH3.
  • a preferred group of Ri may be defined as -C(O)CH 2 -O-C(O)(CH 2 ) n X, wherein n is an integer in the range of 1 to 10, preferably in the range of 2 to 5, more preferably in the range of 3 to 4, yet more preferably 3, and X is selected from the group consisting of -CH 3, -OH and COOH, preferably X is -CH 3 .
  • R 2 may preferably be selected from the group consisting of -NH-(C r C 6 -acyl), -NH-(C r C 6 -alkyl), -NH-(d-C 6 -alkoxy), -N(Ci-C 6 -acyl)(Ci-C 6 -acyl), -N(Ci-C 6 -acyl)(Ci-C 6 -alkyl), -N(C r C 6 -acyl) (C r C 6 -alkoxy), - N(Ci-C 6 -alkyl)(Ci-C 6 -alkyl), -N(Ci-C 6 -alkyl)(CrC 6 -alkoxy), -N(Ci-C 6 -alkoxy)(C r C 6 - alkoxy), -heterocyclyl, -C(O)CH 2 -O-(Ci-C 6
  • R 2 may be selected from the group consisting of -NH-(CrC 6 - acyl), -NH-(Ci-C 6 -alkyl), -NH-(C r C 6 -alkoxy), -N(Ci-C 6 -acyl)(Ci-C 6 -acyl), -N(CrC 6 - acyl)(Ci-C 6 -alkyl), -N(Ci-C 6 -acyl) (Ci-C 6 -alkoxy), -N(Ci-C 6 -alkyl)(C r C 6 -alkyl), -N(CrC 6 - alkyl)(Ci-C 6 -alkoxy), -N(Ci-C 6 -alkoxy)(C r C 6 -alkoxy), -heterocyclyl, and -(C r C 6 -acyl); wherein any alkyl, acyl, alkoxy
  • R 2 is selected from the group consisting of -COCH 2 OCO(CH 2 ) 3 CH 3 , -COCH 2 OH, -COCH 3 , -NH 2 , -H, -OH, and -
  • any alkyl, acyl, or alkoxy moiety of R 2 optionally is substituted with one or more of Ci-C 3 -alkyl, Ci-C 2 -alkoxy, -OH, halogen, -NH 2 , -NH-(Ci-C 4 -alkyl), or - N(Ci-C 4 -alkyl)(Ci-C 4 -alkyl).
  • R 2 is selected from the group consisting of -COCH 2 OCO(CH 2 ) 3 CH 3 , -COCH 2 OH, -COCH 3 , and
  • any alkyl, acyl, or alkoxy moiety of R 2 optionally is substituted with one or more of Ci-C 3 -alkyl, Ci-C 2 -alkoxy, -OH, halogen, -NH 2 , -NH-(Ci-C 4 -alkyl), or - N(Ci-C 4 -alkyl)(Ci-C 4 -alkyl).
  • the lipophilic anthracyclines may be selected from the group consisting of OctADR (adriamycin octanoyl-hydrazone), MRA-CN (3'-deamino-3'-(3-cyano-4- morpholinyl)adriamycin), AD32 (valrubicin), AD41 , AD143, AD194, AD198, AD199, AD201 , AD202, and AD288, or mixtures thereof, or pharmaceutical acceptable salts, solvates or prodrugs thereof.
  • the lipophilic anthracyclines may also be selected from the group consisting of derivatives of OctADR, MRA-CN, AD32, AD41 , AD143, AD194, AD198, AD199, AD201 , AD202, AD288, and mixtures thereof.
  • the lipophilic anthracycline is valrubicin, which may also be denoted AD32.
  • derivatives as used herein is meant a compound, in which one atom or a group of atoms is replaced with another atom or a group of atoms.
  • the size of the lipophilic anthracycline may also be important, because if said molecule is too large, it may be difficult for the molecule to reach the cells, which are afflicted by hyperproliferation.
  • the lipophilic anthracycline is preferably of a size enabling it to pass the skin barrier and penetrate epidermis, to reach the cells in the epidermis in need of treatment.
  • the ease of penetration may also be improved by adding a penetration enhancer to the pharmaceutical composition.
  • Preferred anthracyclines according to the present invention are capable of penetrating into a multilayered epithelium, preferably more than one cell layer, such as
  • cell layers for example approximately 3 cell layers, such as approximately 4 cell layers, for example approximately 4 to 6 cell layers, such as approximately 6 to 8 cell layers, for example approximately 8 to 10 cell layers, such as approximately 10 to 12 cell layers, for example approximately 12 to 15, such as 15 to 20 cell layers into a multilayered epithelium.
  • 50% by weight of the anthracycline more preferred 60%, even more preferred 70%, yet even more preferred 80%, especially preferred 90% by weight of the anthracycline has penetrated at least 2 cell layers, preferably at least 3 cell layers, more preferably at least 4 cell layers, even more preferably in the range of 4 to 20 cell layers, yet more preferably in the range of 6 to 20 cell layers, yet more preferably in the range of 8 to 20, even more preferably in the range of 12 to 20 cell layers.
  • preferred anthracyclines according to the present invention are not locally toxic when applied topically to a body surface of an individual, more preferably, the anthracyclines are not, or are only mildly irritant, when applied to a body surface of an individual in an effective dose.
  • a compound such as an anthracycline is not, or only mildly irritant, can be determined as described herein below in the section "Skin irritation".
  • a preferred lipophilic anthracycline is valrubicin, which is very lipophilic due to the less ionisation compared to other anthracyclines. Accordingly, valrubicin may pass the cell membrane and enter the cytoplasm of cells in a fast manner.
  • alkyl includes saturated monovalent hydrocarbon radicals having straight or branched moieties.
  • alkyl moieties include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, and neopentyl.
  • Alkyl is preferably CrC 6 alkyl, i.e. groups containing from 1 to 6 carbon atoms, and for some embodiments of the present invention, more preferably CrC 4 alkyl, such as e.g. CrC 3 alkyl.
  • acyl refers to formyl as well as other alkyl substituted carbonyl groups, wherein “alkyl” is as defined above.
  • acyl includes groups such as (Ci-C 6 )alkanoyl (e.g., formyl, acetyl, propionyl, butyryl, valeryl, caproyl, t-butylacetyl, etc.).
  • alkoxy means an -O-alkyl group wherein “alkyl” is as defined above. Examples include, but are not limited to methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy, 2-pentyloxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, and 3-methylpentoxy.
  • Alkoxy is preferably CrC ⁇ alkoxy, i.e. groups containing from 1 to 6 carbon atoms, and for some embodiments of the present invention, more preferably CrC 4 alkoxy, such as e.g. Cr C 2 alkoxy.
  • heterocyclyl refers to non-aromatic cyclic groups containing one or more heteroatoms selected from O, S and N. Preferably from one to four heteroatoms, more preferably from one to two heteroatoms. Heterocyclyl groups also include groups that are substituted with one or more oxo moieties. Examples of heterocyclyl include, but are not limited to morpholinyl, piperidinyl, piperazinyl, 1 ,2,3,6- tetrahydropyridinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl,
  • tetrahydrothiopyranyl and thiomorpholinyl.
  • morpholiny as e.g. in MRA-CN.
  • Halogen includes fluoro, chloro, bromo and iodo.
  • any alkyl, acyl, alkoxy, or heterocyclyl moiety are "optionally substituted"
  • the moiety in question may be unsubstituted or optionally substituted with one of more substituents (typically, one to three substituents) independently selected from the group of substituents listed.
  • pharmaceutical acceptable salt, solvate or prodrug refers to those acid and base additions salts, solvates, and prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.
  • Pharmaceutically acceptable acid and base addition salts refers to the relatively non- toxic, inorganic and organic addition salts of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds, or by subsequently reacting the purified compound in its free acid or base form with a suitable organic or inorganic compound and isolating the salt thus formed.
  • the compounds of formula (I) of this invention are basic compounds, they are all capable of forming a wide variety of different salts with various inorganic and organic acids.
  • the pharmaceutically acceptable acid addition salts of the basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner.
  • the free base form may be
  • the free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base for purposes of the present invention.
  • Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metal hydroxides, or of organic amines.
  • metals used as cations are sodium, potassium, magnesium, calcium, and the like.
  • suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine, and procaine.
  • the base addition salts of acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner.
  • the free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in a conventional manner.
  • the free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention.
  • Salts may be prepared from inorganic acids sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, phosphorus, and the like.
  • Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate mesylate, glucoheptonate, lactobionate, laurylsulphonate and isethionate salts, and the like.
  • Salts may also be prepared from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. and the like.
  • organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. and the like.
  • Representative salts include acetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like.
  • Pharmaceutically acceptable salts may include cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations including, but not limited to, ammonium, tetramethylammonium,
  • the compounds of the present invention may exist in unsolvated forms as well as in solvated forms, including hydrated forms.
  • the solvated forms, including hydrated forms are equivalent to unsolvated forms and are intended to be
  • prodrug refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formulae, for example, by hydrolysis. A thorough discussion is provided in T. Higuchi and V Stella, "Pro-drugs as Novel Delivery
  • prodrugs include pharmaceutically acceptable, non-toxic esters of the compounds of the present invention, including C-i-C ⁇ alkyl esters wherein the alkyl group is a straight or branched chain. Acceptable esters also include C 5 -C 7 cycloalkyl esters as well as arylalkyl esters such as, but not limited to benzyl. CrC 4 alkyl esters are preferred. Esters of the compounds of the present invention may be prepared according to conventional methods "March's Advanced Organic Chemistry, 5 th Edition". M. B. Smith & J. March, John Wiley & Sons, 2001.
  • Compounds of formula (I) may contain chiral centers and therefore may exist in different enantiomeric and diastereomeric forms.
  • This invention relates to all optical isomers and all stereoisomers of compounds of the formula (I), both as racemic mixtures and as individual enantiomers and diastereoismers ((+)- and (-)-optically active forms) of such compounds, and mixtures thereof, and to all pharmaceutical compositions and methods of treatment defined below that contain or employ them, respectively.
  • Individual isomers can be obtained by known methods, such as optical resolution, optically selective reaction, or chromatographic separation in the
  • the pharmaceutical composition according to the present invention may comprise the lipophilic anthracycline in an amount of at least 0.1 %, preferably at least 0.5%, more preferably at least 1 % of said lipophilic anthracycline (w/w %).
  • the pharmaceutical composition according to the present invention may comprise the lipophilic anthracycline in an amount of 0.1 to 10 w/w %, such as e.g., from 0.1 to 8 w/w %, from 0.1 to 5 w/w %, from 1 to 5 w/w % ,from 0.1 to 2.5 w/w %, from 0.1 to 1.5 w/w %, from 0.25 to 1.25 w/w %, from 0.5 to 2.5 w/w %, from 0.5 to 2.0 w/w %, from 0.5 to 1.5 w/w %, or of about 1.0 w/w %. More preferably in an amount of from 0.25 to 1.25 w/w %, and more preferably in an amount of 1.0 w/w %.
  • compositions according to the present invention is pharmaceutical compositions comprising
  • composition further comprises an aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 6, and wherein the water content of the pharmaceutical composition is less than 30%.
  • the pharmaceutical composition may preferably be in a form selected from the group consisting of a water in oil emulsion, an emulsified gel, a gel, and an oil in water emulsion; more preferably a water in oil emulsion or an emulsified gel.
  • compositions may also be a composition comprising only a lipid phase, such as an ointment.
  • the composition is a water in oil emulsion.
  • the composition is an emulsified gel.
  • the composition is an ointment, gel or an oil in water emulsion.
  • compositions may comprise more than one different anthracycline, such as 2, for example 3, such as 4, for example 5, such as more than 5 different anthracyclines.
  • all of said anthracyclines are lipophilic anthracyclines, preferably any of the lipophilic anthracyclines described herein above in the section "lipophilic anthracycline".
  • compositions may comprise any suitable amount of said lipophilic anthracycline. It is however preferred that all of the lipophilic anthracycline within the compositions is in solution, accordingly the composition should preferably not contain more lipophilic anthracycline than what is soluble in the composition.
  • the pharmaceutical composition may comprise at least 0.1 %, preferably at least 0.5%, more preferably at least 1 % of said lipophilic anthracycline.
  • the composition may comprise in the range of 0.1% to 30%, such as in the range of 0.1% to 20%, for example in the range of 0.1 % to 10%, such as in the range of 0.1% to 5%, for example in the range of 0.5% to 30%, such as in the range of 0.5% to 20%, for example in the range of 0.5% to 10%, such as in the range of 0.5% to 5%, for example in the range of 0.5% to 3%, such as in the range of 0.5% to 1.5%, for example in the range of 1 % to 30%, such as in the range of 1 % to 20%, for example in the range of 1 % to 10%, such as in the range of 1% to 5%, for example in the range of 1 % to 3%, such as in the range of 1 % to 2%, and preferably in the range of 0.25 to 1.25%.
  • the % is
  • said solution may comprise at least 0.1 %, preferably at least 0.5%, more preferably at least 1% of said lipophilic anthracycline.
  • said solution may comprise in the range of 0.1% to 30%, such as in the range of 0.1 % to 20%, for example in the range of 0.1% to 10%, such as in the range of 0.1% to 5%, for example in the range of 0.5% to 30%, such as in the range of 0.5% to 20%, for example in the range of 0.5% to 10%, such as in the range of 0.5% to 5%, for example in the range of 0.5% to 3%, such as in the range of 0.5% to 1.5%, for example in the range of 1 % to 30%, such as in the range of 1 % to 20%, for example in the range of 1 % to 10%, such as in the range of 1% to 5%, for example in the range of 1 % to 3%, such as in the range of 1% to 2%.
  • said solution may comprise at least 0.1%, preferably at least 0.5%, more preferably at least 1 % of said lipophilic anthracycline.
  • said gel, cream, lotion or ointment may comprise in the range of 0.1 % to 10%, such as in the range of 0.1 % to 5%, for example in the range of 0.5% to 10%, such as in the range of 0.5% to 5%, for example in the range of 0.5% to 3%, such as in the range of 0.5% to 1.5%, for example in the range of 1 % to 10%, such as in the range of 1 % to 5%, for example in the range of 1 % to 3%, such as in the range of 1 % to 2%.
  • the present invention discloses that in order for the anthracycline to be effective after local administration, e.g. topical application, it is important that the pharmaceutical composition is formulated in such a way that the anthracycline is kept dissolved when penetrating to the cells to be treated, i.e. to the hyperproliferative cells.
  • dermal hyperproliferation preferably epidermal hyperproliferation, such as e.g.
  • the lipophilic anthracycline is kept dissolved when penetrating the tissue on its passage to the cells in need of treatment, which for example may be the epidermis of the skin or a mucosal epithelial membrane . Consequently, according to the present invention it is most preferred that the lipophilic anthracycline is kept dissolved in a vehicle. It is also preferred that the vehicle does not evaporate, or at least that some of the vehicle does not evaporate when applied to the surface of the skin, but is capable of delivering the anthracycline to the target location.
  • the excipients such as the oil phase carriers, the solubilizers, and the co- surfactants, used in the formulation of the present invention must be chosen to provide said solubilization.
  • the solubility of the lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic acid, and the solubilizers, and the co- surfactants, used in the formulation of the present invention must be chosen to provide said solubilization. Hence, it is important that the solubility of the lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic
  • anthracyclines in at least some of these, preferably in the majority of the individual excipients is of a certain degree. It is also preferred that the lipophilic anthracycline is fully dissolved in parts of the final
  • the present inventors have found that the pH of the formulation is important to ensure a satisfactory stability of the pharmaceutical composition, including a satisfactory stability of the active compound in question.
  • the composition designated "ValstarTM” comprising the lipophilic anthracycline valrubicin must be stored at 2-8 0 C. It has been found by the present inventors that by keeping the pH of the aqueous phase at pH 6 or below, preferably from pH 2.2 to pH 6, then the pharmaceutical composition may be stored at about 25 ° C and 60 RH%.
  • the pharmaceutical composition according to the present invention comprises an aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 6.0.
  • the pH of said one or more buffering system is in the range of pH 2.2 to pH 5.0, such as e.g. of pH 2.2 to 4.5, of pH 2.2 to 4.2, more preferably of pH 2.2 to 4.0, even more preferably of pH 2.2 to 3.5, yet even more preferably of pH 2.5 to 3.5, and yet even more preferably of pH 2.5 to 3.0, and most preferably of about pH 2.5, such as pH 2.5.
  • aqueous phase is intended to mean the aqueous part of the composition, i.e. the aqueous phase may be part of a carrier or excipient system, such as e.g., an oil in water emulsion (o/w), a water in oil emulsion (w/o), or an emulsified gel.
  • a carrier or excipient system such as e.g., an oil in water emulsion (o/w), a water in oil emulsion (w/o), or an emulsified gel.
  • o/w oil in water emulsion
  • w/o water in oil emulsion
  • emulsified gel e.g., an oil in water emulsion (o/w), a water in oil emulsion (w/o), or an emulsified gel.
  • the aqueous phase is thus not necessarily a separate aqueous phase as such.
  • the pH as used herein is specified as the pH of
  • the pH will be that of the added aqueous buffering system.
  • buffering system is intended to mean a mixture of a weak acid and its conjugate base or a weak base and its conjugate acid.
  • the buffering system may furthermore be mixtures of one or more such acid/base pairs.
  • the buffering agent may be any buffering agent, preferably a buffering agent which is not, or only mildly irritant, when applied to skin.
  • Non-limiting examples of buffering agents that may be used alone or in combinations are citric acid (e.g. Citric acid/Sodium citrate), acetic acid (e.g. Acetic acid/Sodium acetate), disodium phosphate (e.g.
  • the buffering system may comprise lactic acid, such as e.g. lactic acid - sodium lactate.
  • the pH of the final pharmaceutical composition is preferably in a range from pH 4.0 to pH 6, as it has been found by the present inventors that lower pH values may provide both stability problems and problems with skin or mucosal membrane irritation.
  • a buffer solution having a pH of about 2.5 is applied in the pharmaceutical formulation according to the present invention, then the skilled person will know that a pH of e.g. pH 4.5 may be obtained in the final pharmaceutical composition by adding the appropriate amount of the buffer solution.
  • a composition comprises slightly alkaline constituents and these are to be neutralised at the same time as the composition is to have an additional buffer capacity at a specific pH value, then a buffer solution being more acidic than the desired final pH may be used.
  • the pharmaceutical composition may preferably comprise sufficient of said buffer system in order to obtain a suitable pH in the entire pharmaceutical composition.
  • the pharmaceutical compositions according to the invention may preferably comprise said buffering system as an aqueous solution comprising a buffering compound in the range of 10 to 300 mM, such as e.g., of 10 to 200 mM, of 20 to 200 mM, of 30 to 15O mM, of 40 to 15O mM, of 40 to 14O mM, or of 40 to 13O mM.
  • the pH in the final pharmaceutical composition may preferably be in a range from pH 4.0 to pH 6, preferably from pH 4.0 to pH 5.5, more preferably from pH 4.0 to pH 5.0, even more preferably from pH 4.2 to pH 4.9.
  • the pH of the final pharmaceutical composition is in a range of pH 4.2 to about 4.9.
  • the buffering compound is preferably in a concentration in a range of 10 to 200 mM, such as e.g. of 20 to 150 mM, of 30 to 100 mM, of 30 to 80 mM, or more preferably of 40 to 60 mM, and even more preferably of about 50 mM, yet more preferably 50 mM.
  • the pH of said buffering system is in the range of pH 2.2 to 4.5, such as e.g. of pH 2.2 to 4.2, preferably of pH 2.2 to 4.0, more preferably of pH 2.2 to 3.5, even more preferably of pH 2.5 to 3.5, and yet even more preferably of pH 2.5 to 3.0, and most preferably of about pH 2.5, such as pH 2.5, and the concentration of the one or more buffering compounds is preferably in a range of 20 to 150 mM, such as e.g. of 30 to 10O mM, of 30 to 80 mM, or more preferably of 40 to 60 mM, and even more preferably of about 50 mM, such as 50 mM.
  • the buffering compound is preferably in a concentration in a range of 50 to 300 mM, such as e.g., of 50 to 200 mM, e.g. of 50 to 175 mM, e.g. of 60 to 140 mM, or more preferably of 75 to 125 mM, and even more preferably of about 100 mM, such as 100 mM.
  • the pH of said buffering system is in the range of pH 2.2 to 4.5, such as e.g. of pH 2.2 to 4.2, preferably of pH 2.2 to 4.0, more preferably of pH 2.2 to 3.5, even more preferably of pH 2.5 to 3.5, and yet even more preferably of pH 2.5 to 3.0, and most preferably of about pH 2.5, such as pH 2.5, and the concentration of the one or more buffering compounds is preferably in a range of 50 to 200 mM, such as e.g., of 50 to 175 mM, e.g.
  • the water content of the pharmaceutical compositions of the invention may preferably be less than 30%, more preferably less than 25%, even more preferably less than 20%, yet even more preferably less than 15%, and yet even more preferably less than 14%. It has for example been found by the present inventors that pharmaceutical
  • compositions according to the invention having a decreased water content are more stable over time. This can for example be seen from the stability study in example 1 1 , where formulation A, having a water content of 35.1%, can be seen to be less stable than formulations VLD32 and emulsified gel 4, having water contents, in the form of the buffer solutions, at about approximately 10% and 13.4%, respectively.
  • the water content of the pharmaceutical formulations of the present invention may preferably be included in the form of an aqueous buffer solution.
  • the choice of oil phase carriers in the compositions of the present invention is also very important. Thus, preferably the oil phase carrier is chosen so that it may aid to carry the anthracycline through the epidermis and deliver the drug at the cells or within the cells to be treated.
  • the pharmaceutical composition according to the present invention comprises one or more oil phase carriers.
  • the one or more oil phase carriers is present in an amount of in the range of 10 to 70%, for example in the range of 10 to 60%, preferably in the range 10 to 55 w/w %, such as e.g., of 10 to 50 w/w %, of 12 to 48 w/w %, of 15 to 44 w/w %, or specifically of about 44 w/w % or specifically of about 15 w/w %, such as 44 w/w % or 15 w/w %.
  • said oil phase carrier is in an amount of 35 to 55 w/w %, more preferably of 35 to 50 w/w %, even more preferably of 40 to 50 w/w %, and most preferably of about 45 w/w %, such as of about 44 w/w %, for example 45 w/w%, such as 44 w/w %.
  • the pharmaceutical compositions is an emulsified gel or a gel
  • said oil phase carrier is in an amount of 10 to 25 w/w %, more preferably of 10 to 20 w/w %, even more preferably of 12 to 18 w/w %, and most preferably of about 15 w/w %, such as 15 w/w%.
  • the pharmaceutical composition may comprise an even larger percentage of said oil phase carrier, such as in the range of 10 to 95%, for example in the range of 10 to 90%, such as in the range of 10 to 80%, preferably in the range of 10 to 70%, such as in the range 10 to 60%.
  • oil phase carrier may be any pharmaceutical acceptable oil phase carrier that will dissolve the active compound and aid carrying the anthracycline through the epidermis.
  • the oil phase carrier may be acylglycerols as for instance a
  • the fatty acid of the acylglycerol is a saturated or unsaturated fatty acid comprising 8 to 26 carbon atoms, more preferred 12 to 24 carbon atoms, even more preferred 16 to 22 carbon atoms.
  • the one or more oil phase carriers may be selected from the group consisting of white soft paraffin, hard paraffin, Crodamol (such as e.g. Crodamol GTCC), glycerol
  • the one or more oil phase carriers may be selected from the group consisting of white soft paraffin, hard paraffin, Crodamol (such as e.g. Crodamol GTCC), and mixtures thereof.
  • the choice of pharmaceutical acceptable solubilizers in the compositions of the present invention is likewise very important, as the lipophilic antracyclines need to have a certain solubility in said solubilizer.
  • the pharmaceutical composition according to the present invention comprises one or more pharmaceutical acceptable solubilizers.
  • the pharmaceutical acceptable solubilizers are present in an amount of 10 to 45 w/w %, such as e.g., of 10 to 40 w/w %, of 12 to 38 w/w %, of 15 to 38 w/w %, of 15 to 35 w/w %, or specifically of about 17% or specifically of about 32 %, such as 17% or 32%.
  • said solubilizer is in an amount of 10 to 25 w/w %, more preferably of 10 to 20 w/w %, even more preferably of 15 to 20 w/w %, and most preferably of about 17 w/w %, such as 17%.
  • said solubilizer is in an amount of 20 to 45 w/w %, more preferably of 25 to 35 w/w %, even more preferably of 30 to 35 w/w %, most preferably of about 32 w/w %, such as 32 w/w%.
  • the pharmaceutical acceptable solubilizers may be any pharmaceutical acceptable solubilizers that will dissolve the active compound and aid in carrying the active compound into the epidermis.
  • the solubilizer may be polyvalent alcohols or mixtures of polyvalent alcohols, in particular divalent alcohols or trivalent alcohols or mixtures thereof. More preferably the one or more pharmaceutical acceptable solubilizers may be selected from the group consisting of propylene glycol, glycerol, and cremophor RH40 (polyoxyl 40 hydrogenated castor oil) or mixtures thereof.
  • At least one of the pharmaceutical acceptable solubilizers may furthermore be characterized as an alcohol comprising at least two free -OH groups.
  • Said solubilizer being an alcohol preferably may be a lower alkyl substituted with at least two -OH groups. More preferably said solubilizer being an alcohol may be selected from the group consisting of glycerol and propylene glycol. The preferred amounts are as specified for the solubilizer immediately herein above.
  • composition according to the present invention furthermore comprises one or more co-surfactants.
  • the co-surfactants may be any co-surfactant giving an acceptable solubility of the active compound.
  • the one or more co-surfactants may be selected from the group consisting of diethylene glycol monoethyl ether (such as e.g. transcutol P), glycofurol (tetrahydrofurfuryl polyethylenglycol), Propylene Glycol Monolaurate (such as e.g. LauroglycolTM 90), and Propylene Glycol Laurate (such as e.g. LauroglycolTM FCC), or mixtures thereof.
  • diethylene glycol monoethyl ether such as e.g. transcutol P
  • glycofurol tetrahydrofurfuryl polyethylenglycol
  • Propylene Glycol Monolaurate such as e.g. LauroglycolTM 90
  • Propylene Glycol Laurate
  • the one or more co-surfactants may comprise diethylene glycol monoethyl ether (such as e.g. transcutol P), and even more preferably transcutol P.
  • the one or more co-surfactants are present in an amount of 5 to 35 w/w %, such as e.g., of 10 to 30 w/w %, of 12 to 27 w/w %, of 15 to 25 w/w %, of 5 to 25 w/w %, of 15 to 35 w/w %, or specifically of about 15% or specifically of about 25 %, such as 15% or 25%.
  • said co-surfactant is transcutol P in an amount of 5 to 25 w/w %, preferably of about 15 w/w %, such as 15%.
  • said co-surfactant is transcutol P in an amount of 15 to 35 w/w %, preferably of about 25 w/w %, such as 25%.
  • At least one of the one or more solubilizers and/or the one or more co-surfactants may furthermore be characterized by
  • a) comprises at least one -OH group
  • c) has a molecular weight of at the most 300.
  • At least one of the one or more solubilizers and/or one of the one or more co-surfactants may be a polyether.
  • the polyether may have the general structure Ri[-O-CH 2 -CH 2 ]-R2, wherein n is an integer in the range of 2 to 6, preferably 2 to 5, Ri and R 2 individually are selected from the group consisting of lower alcohols, lower alkyl and 5 to 6 membered rings. More preferably the polyether is selected from the group consisting of diethylene glycol monoethyl ether and glycofurol
  • the amount of said polyether in the composition may preferably be in the range of 5 to 50 w/w%, preferably in the range of 10 to 30 w/w%.
  • the polyether may furthermore be characterized by the solubility of the lipophilic anthracyclines. Accordingly, in a preferred embodiment, the solubility of valrubicin in said polyether is at least 5% w/w, preferably at least 10% w/w, even more preferably at least 20% w/w.
  • the polyether may preferably be a polyether, wherein the percentage peak purity of valrubicin after storage therein for 2 weeks at 25 0 C and 60 %RH, is at least 80%, preferably at least 85%, more preferably at least 90%.
  • the pharmaceutical compositions according to the present invention may further comprise one or more emulsifiers and/or one or more gel forming polymers.
  • the emulsifier may be any emulsifier known to the person skilled in the art that is suitable for pharmaceutical formulations for topical administration.
  • This emulsifier may be an ester originating from an organic acid having 3 to 18 carbon atoms and an alcohol having 3 to 18 carbon atoms and mixtures thereof.
  • the emulsifier may for example be selected from the group consisting of PEG-30 dipolyhydroxystearate, polyglyceryl-2- dipolyhydroxystearate, polyglyceryl-3-diisostearate, lauryl lactate, cetearyl
  • the gel forming polymer may be any gel forming polymer known to the person skilled in the art that is suitable for preparing
  • said one or more emulsifiers and/or one or more gel forming polymers is present in an amount of 0.1 to 10 w/w %, such as e.g., of 0.5 to 8 w/w %, of 1 to 6 w/w %, of 1 to 5 w/w %, of 1 to 4 w/w %, of 1 to 3 w/w %, or specifically of about 2 w/w% or specifically about 2.5%, such as 2 w/w % or 2.5%.
  • the pharmaceutical compositions is a water in oil emulsion or an oil in water emulsion
  • the composition comprises one or more emulsifiers in the above specified amounts. More preferably, when the composition is a water in oil emulsion, said one or more emulsifiers may be selected from the group consisting of Dow Corning emulsifier 10, and Abil Em 90. Even more preferably Dow Corning emulsifier 10.
  • the pharmaceutical compositions is an emulsified gel or a gel, it is preferred that the composition comprises one or more gel forming polymers in the above specified amounts.
  • said one or more gel forming polymers may be selected from the group consisting of hydroxypropyl cellulose (such as e.g. HPC HF), hydroxyethyl cellulose (such as e.g. HEC HF), Sodium
  • Polyacrylate Cetyl Hydroxy Ethyl Cellulose, and Polyquaternium 10. Even more preferably hydroxy propyl cellulose (such as e.g. HPC HF).
  • compositions according to the present invention may further comprise a pharmaceutical acceptable alcohol, preferably ethanol.
  • a pharmaceutical acceptable alcohol preferably ethanol.
  • the alcohol may be included to aid the solubility, but at the same time it is undesirable to have a large content of said alcohol, such as e.g. ethanol, as this may increase irritation of the skin or other epithelial tissue.
  • the solubility of the active compound in the composition relies on the presence of the alcohol, then after application the alcohol may evaporate and leave the active compound undissolved, hereby hindering the absorption and the penetration to the relevant tissue.
  • the pharmaceutical acceptable alcohol may be present in an amount of 0.1 to 15 w/w %, such as e.g., of 0.5 to 15 w/w %, of 1 to 13 w/w %, preferably of 2 to 13 w/w %, more preferably of 3 to 13 w/w %, and even more preferably of 4 to 12 w/w %, such as e.g., of 5 to 10 w/w %, or specifically of about 5 w/w % or specifically of about 10 w/w %, such as 5 w/w % or 10 w/w %.
  • the pharmaceutical compositions is a water in oil emulsion
  • said pharmaceutical acceptable alcohol is present in an amount of 0.1 to 10 w/w %, more preferably of 0.5 to 10 w/w %, even more preferably of 1 to 10 w/w %, yet even more preferably of 2 to 8 w/w %, and specifically of about 5 w/w %, such as 5 w/w %.
  • the pharmaceutical compositions is an emulsified gel or a gel
  • said pharmaceutical acceptable alcohol is present in an amount of 1 to 15 w/w %, more preferably of 2 to 15 w/w %, even more preferably of 5 to 15 w/w %, yet even more preferably of 8 to 13 w/w %, and specifically of about 10 w/w %, such as 10 w/w %.
  • the pharmaceutical compositions according to the present invention may further comprise one or more antioxidants.
  • said one or more antioxidants may be any pharmaceutically acceptable antioxidants known to the skilled person.
  • said antioxidants are fat soluble antioxidants, due to the lipophilic character of the anthracyclines of the present invention.
  • said one or more antioxidants may be selected from the group consisting of Ascorbyl palmitate, Alpha tocopherol, and mixtures thereof. Said one or more antioxidants may be present in an amount of 0.01 to 0.15 w/w %, such as e.g. of 0.01 to 0.1 w/w %, of 0.01 to 0.08 w/w %, of 0.02 to 0.08 w/w %, of 0.03 to 0.07 w/w %, or specifically of about 0.05 w/w %, such as 0.05 w/w %.
  • the pharmaceutical compositions according to the present invention may further comprise one or more stabilizers and/or preservatives. Generally said stabilizers and/or preservatives may be any stabilizers and/or preservatives well known to the person skilled in the art.
  • said one or more stabilizers may at least comprise an EDTA salt, such as EDTA disodium.
  • Said one or more stabilizers may be present in an amount of 0.01 to 0.1 w/w %, such as e.g. of 0.01 to 0.08 w/w %, of 0.01 to 0.06 w/w %, preferably of 0.01 to 0.04 w/w %, or specifically of about 0.02 w/w %, such as 0.02 w/w%.
  • said one or more preservatives is selected from the group consisting of Phenoxy ethanol, sodium benzoate, sorbic acid, potassium sorbate, benzoic acid, and parabens, or mixtures thereof. More preferably said preservative is phenoxy ethanol. Said one or more preservatives may be present in an amount of 0.01 to 5 w/w %, of 0.01 to 2 w/w %, such as e.g., of 0.1 to 1.5 w/w %, preferably of 0.5 to 1.25 w/w %, or specifically of about 1 w/w %, such as 1 w/w%.
  • the preferred preservatives may furthermore be characterised according to structure. Accordingly, the preferred preservatives may comprise an aromatic ring substituted with an ether substituted with at least one free -OH group. Furthermore the substituted aromatic may have the general structure: aromatic ring-O-(CH 2 )n-OH, wheren n is an integer in the range of 1 to 6, preferably 1 to 3.
  • the aromatic ring may furthermore preferably be phenyl, and the preservative may preferably be phenoxyethanol.
  • the solubility of valrubicin in said preservative may preferably be at least 5% w/w, preferably at least 10% w/w.
  • the stability of the pharmaceutical composition is likewise of importance, including the stability of the active compound, and may be used in the characterisation of the preservative.
  • the preservative may preferably be a preservative, wherein the percentage peak purity of valrubicin after storage therein for 2 weeks at 25 0 C is at least 80%, preferably at least 85%, more preferably at least 90%.
  • the pharmaceutical composition of the present invention further comprises a penetration enhancer, which aids the penetration of the
  • penetration enhancer a substance that alters the skin structure thereby allowing other chemical substances to penetrate deeper into the skin or other tissue in question.
  • the penetration enhancer may be present in the aqueous and/or the oily phase and is preferably selected from the group consisting of propylene glycol, panthenol, behenyl alcohol, hyaluronic acid and mixtures thereof. More preferably the penetration enhancer may be selected from the group consisting of propylene glycol, panthenol, behenyl alcohol, and mixtures thereof.
  • compositions according to the present invention may further comprise at least one compound having a molecular weight in the range of 50 and 1000 g/mol, more preferred in the range of 60 and 700 g/mol, even more preferred in the range of 70 and 500 g/mol, where said further compound is selected from the group consisting of aldehydes, ketones, esters, ethers, sugars, and proteins. Any compound known by the skilled person to be suitable for use in compositions for topical application may be used.
  • some component of the compositions of the invention can possess multiple functions.
  • a given component can act as both a solubilizer and a co-solubilizer.
  • the function of a given component can be considered singular, even though its properties in other connections may allow multiple functionalities.
  • compositions of the present invention may further comprise one or more additives in addition to the excipients described herein above selected from the group consisting of emollients, humectants, skin preparing agents, preservatives, colouring agents and acidity regulating agents.
  • the acidity regulating agent is preferably any of the buffering systems described herein above. Any suitable agent known by the skilled person may be used in the compositions.
  • Humectants may be added to the composition.
  • humectants may be added in order to obtain a formulation which may reduce the dryness of the skin afflicted with said hyperproliferative disorders and to improve patient compliance by having a "good feel".
  • good feel is meant a composition, which when applied to normal skin is non, or only mildly, irritant and preferably may be non greasy.
  • Humectants are characterised by being substances with water attracting properties. Humectants differ in water-binding capacity as well as in ability to penetrate and influence the degree of skin hydration.
  • humectants which can be used in the present invention, are propylene glycol, D- pantothenic acid, hyaluronic acid, and alpha-hydroxy acids, such as lactic acid, glycolic acid and tartaric acid.
  • the humectants may be selected from the group consisting of propylene glycol, D-pantothenic acid, and alpha-hydroxy acids, such as e.g. lactic acid, glycolic acid and tartaric acid.
  • compositions of the present invention may furthermore comprise further additives providing said above-mentioned "good feel", specifically one or more additives giving a smooth feel, ease of spreading and reduced tackiness, such as e.g. Dimethicone 350 (Dow Corning (R) Q7-9120 Silicone fluid).
  • further additives providing said above-mentioned "good feel", specifically one or more additives giving a smooth feel, ease of spreading and reduced tackiness, such as e.g. Dimethicone 350 (Dow Corning (R) Q7-9120 Silicone fluid).
  • Said one or more further additives may preferably be present in an amount of 1 to 15 w/w %, such as e.g., of 1 to 12 w/w %, of 1 to 10 w/w %, of 2 to 8 w/w %, of 3 to 7 w/w %; more preferably in an amount of 1 to 10 w/w %; even more preferably of 2 to 8 w/w %; specifically of about 5%.
  • the composition comprises Dimethicone 350.
  • the composition comprises Dimethicone 350 in an amount of amount of 1 to 15 w/w %, such as e.g., of 1 to 12 w/w %, of 1 to 10 w/w %, of 2 to 8 w/w %, of 3 to 7 w/w %; more preferably in an amount of 1 to 10 w/w %; even more preferably of 2 to 8 w/w %; specifically of about 5%.
  • the pharmaceutical composition is an water in oil composition comprising an aqueous phase and an oily phase, said oily phase comprising at least one lipophilic anthracycline, an alcohol having a molecular weight between 70 and 500 g/mol, an oil having a molecular weight between 500 and 1100 g/mol, and an emulsifier.
  • the pharmaceutical composition comprises
  • composition further comprises an aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 6.0, preferably from pH 2.2 to pH 5.0, and wherein the water content of the pharmaceutical composition is less than 30%; said pharmaceutical composition optionally further comprises
  • composition optionally further comprises
  • composition may comprise any further excipients or active compounds as described herein above or below.
  • This pharmaceutical composition may preferably be used in the treatment of conditions as described herein in the section "clinical conditions”.
  • the pharmaceutical composition comprises
  • composition further comprises an aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 6.0, preferably from pH 2.2 to pH 5.0, and wherein the water content of the pharmaceutical composition is less than 30%.
  • a pharmaceutical acceptable alcohol preferably ethanol
  • said pharmaceutical composition may comprise any further excipients or active compounds as described herein above or below. This pharmaceutical composition may preferably be used in the treatment of conditions as described herein in the section "clinical conditions".
  • the pharmaceutical composition comprises
  • composition further comprises an aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 5.0, and wherein the water content of the pharmaceutical composition is less than 30%, preferably less than 20%;
  • said pharmaceutical composition optionally further comprises
  • said pharmaceutical composition optionally further comprises
  • composition may comprise any further excipients or active compounds as described herein above or below. This pharmaceutical composition may preferably be used in the treatment of conditions as described herein in the section
  • the pharmaceutical composition comprises
  • composition further comprises an aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 5.0, and wherein the water content of the pharmaceutical composition is less than 30%, preferably less than 20%.
  • composition may comprise any further excipients or active compounds as described herein above or below.
  • This pharmaceutical composition may preferably be used in the treatment of conditions as described herein in the section "clinical conditions”.
  • the pharmaceutical composition comprises
  • oil phase carriers selected from the group consisting of white soft paraffin, hard paraffin, Crodamol, and mixtures thereof;
  • one or more co-surfactants selected from the group consisting of diethylene glycol monoethyl ether, glycofurol, Propylene Glycol Monolaurate, and Propylene Glycol Laurate, or mixtures thereof; preferably the one or more co- surfactants may comprise diethylene glycol monoethyl ether; and more preferably the one or more co-surfactants may be transcutol P; and
  • composition further comprises an aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 5.0, and wherein the water content of the pharmaceutical composition is less than 30%, preferably less than 20%;
  • said pharmaceutical composition optionally further comprises
  • emulsifiers selected from the group consisting of Dow Corning emulsifier 10, and Abil Em 90, and/or one or more gel forming polymers selected from the group consisting of hydroxypropyl cellulose, hydroxyethyl cellulose, Sodium Polyacrylate, Cetyl Hydroxy Ethyl Cellulose, and Polyquaternium 10;
  • said pharmaceutical composition optionally further comprises
  • composition may comprise any further excipients or active compounds as described herein above or below.
  • the lipophilic anthracycline may preferably be selected from the group consisting of OctADR, MRA-CN, AD32 (valrubicin), AD41 , AD143, AD194, AD198, AD199, AD201 , AD202, and AD288, or mixtures thereof, or pharmaceutical acceptable salts, solvates or prodrugs thereof; more preferably valrubicin.
  • This pharmaceutical composition may preferably be used in the treatment of conditions as described herein in the section "clinical conditions".
  • the pharmaceutical composition comprises
  • one or more co-surfactants selected from the group consisting of diethylene glycol monoethyl ether, glycofurol, Propylene Glycol Monolaurate, and Propylene Glycol Laurate, or mixtures thereof; preferably the one or more co- surfactants may comprise diethylene glycol monoethyl ether; and more preferably the one or more co-surfactants may be transcutol P;
  • emulsifiers selected from the group consisting of Dow Corning emulsifier 10, and Abil Em 90, and/or one or more gel forming polymers selected from the group consisting of hydroxypropyl cellulose, hydroxyethyl cellulose, Sodium Polyacrylate, Cetyl Hydroxy Ethyl Cellulose, and Polyquaternium 10;
  • composition further comprises an aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 5.0, and wherein the water content of the pharmaceutical composition is less than 30%, preferably less than 20%.
  • composition may comprise any further excipients or active compounds as described herein above or below.
  • the lipophilic anthracycline may preferably be selected from the group consisting of OctADR, MRA-CN, AD32 (valrubicin), AD41 , AD143, AD194, AD198, AD199, AD201 , AD202, and AD288, or mixtures thereof, or pharmaceutical acceptable salts, solvates or prodrugs thereof; more preferably valrubicin.
  • This pharmaceutical composition may preferably be used in the treatment of conditions as described herein in the section "clinical conditions".
  • the pharmaceutical composition is a water in oil emulsion comprising
  • composition further comprises an aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 4.2, and wherein the water content of the pharmaceutical composition is less than 30%, preferably less than 20%; said pharmaceutical composition optionally further comprises
  • said pharmaceutical composition optionally further comprises
  • composition may comprise any further excipients or active compounds as described herein above or below.
  • This pharmaceutical composition may preferably be used in the treatment of conditions as described herein in the section "clinical conditions".
  • the pharmaceutical composition is a water in oil emulsion comprising
  • composition further comprises an aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 4.2, and wherein the water content of the pharmaceutical composition is less than 30%, preferably less than 20%.
  • composition may comprise any further excipients or active compounds as described herein above or below.
  • This pharmaceutical composition may preferably be used in the treatment of conditions as described herein in the section "clinical conditions”.
  • the pharmaceutical composition is a water in oil emulsion comprising
  • composition further comprises an aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 4.2, and wherein the water content of the pharmaceutical composition is less than 30%, preferably less than 20%;
  • said pharmaceutical composition optionally further comprises v) 1-5 w/w % of one or more emulsifiers;
  • said pharmaceutical composition optionally further comprises
  • composition may comprise any further excipients or active compounds as described herein above or below.
  • This pharmaceutical composition may preferably be used in the treatment of conditions as described herein in the section "clinical conditions”.
  • the pharmaceutical composition is a water in oil emulsion comprising
  • composition further comprises an aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 4.2, and wherein the water content of the pharmaceutical composition is less than 30%, preferably less than 20%.
  • composition may comprise any further excipients or active compounds as described herein above or below.
  • This pharmaceutical composition may preferably be used in the treatment of conditions as described herein in the section "clinical conditions".
  • the pharmaceutical composition is a water in oil emulsion comprising
  • oil phase carriers selected from the group consisting of white soft paraffin, hard paraffin, Crodamol, and mixtures thereof;
  • composition further comprises an aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 4.2, and wherein the water content of the pharmaceutical composition is less than 30%, preferably less than 20%;
  • said pharmaceutical composition optionally further comprises
  • emulsifier 10 1-5 w/w % of one or more emulsifiers selected from the group consisting of Dow Corning emulsifier 10 and Abil Em 90, preferably Dow Corning emulsifier 10;
  • said pharmaceutical composition optionally further comprises
  • composition may comprise any further excipients or active compounds as described herein above or below.
  • the lipophilic anthracycline may preferably be selected from the group consisting of OctADR, MRA-CN, AD32 (valrubicin), AD41 , AD143, AD194, AD198, AD199, AD201 , AD202, and AD288, or mixtures thereof, or pharmaceutical acceptable salts, solvates or prodrugs thereof; more preferably valrubicin.
  • This pharmaceutical composition may preferably be used in the treatment of conditions as described herein in the section "clinical conditions".
  • the pharmaceutical composition is a water in oil emulsion comprising
  • oil phase carriers selected from the group consisting of white soft paraffin, hard paraffin, Crodamol, and mixtures thereof;
  • emulsifier 10 1-5 w/w % of one or more emulsifiers selected from the group consisting of Dow Corning emulsifier 10 and Abil Em 90, preferably Dow Corning emulsifier 10;
  • composition further comprises an aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 4.2, and wherein the water content of the pharmaceutical composition is less than 30%, preferably less than 20%.
  • composition may comprise any further excipients or active compounds as described herein above or below.
  • the lipophilic anthracycline may preferably be selected from the group consisting of OctADR, MRA-CN, AD32 (valrubicin), AD41 , AD143, AD194, AD198, AD199, AD201 , AD202, and AD288, or mixtures thereof, or pharmaceutical acceptable salts, solvates or prodrugs thereof; more preferably valrubicin.
  • This pharmaceutical composition may preferably be used in the treatment of conditions as described herein in the section "clinical conditions".
  • composition is an emulsified gel comprising
  • composition further comprises an aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 4.2, and wherein the water content of the pharmaceutical composition is less than 30%, preferably less than 20%;
  • said pharmaceutical composition optionally further comprises
  • said pharmaceutical composition optionally further comprises
  • composition may comprise any further excipients or active compounds as described herein above or below.
  • This pharmaceutical composition may preferably be used in the treatment of conditions as described herein in the section "clinical conditions”.
  • the pharmaceutical composition may comprise any further excipients or active compounds as described herein above or below.
  • composition is an emulsified gel comprising
  • composition further comprises an aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 4.2, and wherein the water content of the pharmaceutical composition is less than 30%, preferably less than 20%.
  • aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 4.2, and wherein the water content of the pharmaceutical composition is less than 30%, preferably less than 20%.
  • said pharmaceutical composition may comprise any further excipients or active compounds as described herein above or below. This pharmaceutical composition may preferably be used in the treatment of conditions as described herein in the section "clinical conditions".
  • the pharmaceutical composition is an emulsified gel comprising
  • composition further comprises an aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 4.2, and wherein the water content of the pharmaceutical composition is less than 30%, preferably less than 20%;
  • said pharmaceutical composition optionally further comprises
  • said pharmaceutical composition optionally further comprises
  • composition may comprise any further excipients or active compounds as described herein above or below.
  • This pharmaceutical composition may preferably be used in the treatment of conditions as described herein in the section "clinical conditions”.
  • the pharmaceutical composition is an emulsified gel comprising
  • composition further comprises an aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 4.2, and wherein the water content of the pharmaceutical composition is less than 30%, preferably less than 20%.
  • aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 4.2, and wherein the water content of the pharmaceutical composition is less than 30%, preferably less than 20%.
  • said pharmaceutical composition may comprise any further excipients or active compounds as described herein above or below. This pharmaceutical composition may preferably be used in the treatment of conditions as described herein in the section "clinical conditions".
  • the pharmaceutical composition is an emulsified gel comprising
  • oil phase carriers selected from the group consisting of white soft paraffin, hard paraffin, Crodamol, and mixtures thereof, more preferably the oil phase carrier may be Crodamol;
  • one or more co-surfactants comprising diethylene glycol monoethyl ether; more preferably the one or more co-surfactants may be transcutol P;
  • composition further comprises an aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 4.2, and wherein the water content of the pharmaceutical composition is less than 30%, preferably less than 20%;
  • said pharmaceutical composition optionally further comprises
  • said pharmaceutical composition optionally further comprises
  • composition may comprise any further excipients or active compounds as described herein above or below.
  • the lipophilic anthracycline may preferably be selected from the group consisting of OctADR, MRA-CN, AD32 (valrubicin), AD41 , AD143, AD194, AD198, AD199, AD201 , AD202, and AD288, or mixtures thereof, or pharmaceutical acceptable salts, solvates or prodrugs thereof; more preferably valrubicin.
  • This pharmaceutical composition may preferably be used in the treatment of conditions as described herein in the section "clinical conditions".
  • the pharmaceutical composition is an emulsified gel comprising i) 0.1-2.5 w/w %, preferably 0.25-1.25 w/w % of a lipophilic anthracycline;
  • oil phase carriers selected from the group consisting of white soft paraffin, hard paraffin, Crodamol, and mixtures thereof, more preferably the oil phase carrier may be Crodamol;
  • one or more co-surfactants comprising diethylene glycol monoethyl ether; more preferably the one or more co-surfactants may be transcutol P;
  • composition further comprises an aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 4.2, and wherein the water content of the pharmaceutical composition is less than 30%, preferably less than 20%.
  • compositions may comprise any further excipients or active compounds as described herein above or below.
  • the lipophilic anthracycline may preferably be selected from the group consisting of OctADR, MRA-CN, AD32 (valrubicin), AD41 , AD143, AD194, AD198, AD199, AD201 , AD202, and AD288, or mixtures thereof, or pharmaceutical acceptable salts, solvates or prodrugs thereof; more preferably valrubicin.
  • This pharmaceutical composition may preferably be used in the treatment of conditions as described herein in the section "clinical conditions".
  • Pharmaceutical compositions - stability may be selected from the group consisting of OctADR, MRA-CN, AD32 (valrubicin), AD41 , AD143, AD194, AD198, AD199, AD201 , AD202, and AD288, or mixtures thereof, or pharmaceutical acceptable salts, solvates or prodrugs thereof; more preferably valrubicin.
  • This pharmaceutical composition may preferably be used in the treatment of conditions as described herein
  • compositions according to the invention are stable, even upon storage at room temperature.
  • the percentage peak purity of the lipophilic anthracycline (such as valrubicin) comprised therein is at least 70%, more preferably at least 80%, yet more preferably at least 90%, yet more preferably at least 95% after storage for 3 months at 25 0 C and 60 %RH. It is also preferred that the percentage recovery of said lipophilic anthracycline (such as valrubicin) is at least 80%, preferably at least 90%, more preferably at least 95%, even more preferably at least 98%, and yet even more preferably 99% after storage for 3 months at 25 0 C and 60 %RH.
  • the percentage recovery of said lipophilic anthracycline is at least 90% after storage of the pharmaceutical composition according to the invention at 25 ° C and 60 %RH for up to and including 12 months, preferably at least 95% after storage for 12 months at 25 0 C and 60 %RH.
  • the stability of the pharmaceutical formulations according to the present invention may additionally be increase by storage at 2-8 ° C, i.e. maximum 8 ° C.
  • the stability at both 25 ° C and 2-8 ° C can be seen from example 1 1 herein.
  • the percentage recovery of said lipophilic anthracycline is at least 90% after storage of the pharmaceutical composition according to the invention at 2-8 ° C for up to and including 12 months, preferably at least 95%, more preferably at least 98%, even more preferably at least 99%, yet even more preferably 99.5%, yet even more preferably 99.9% after storage for 12 months at 2-8 ° C.
  • the percentage peak purity of the lipophilic anthracycline (such as valrubicin) comprised therein is at least 70%, more preferably at least 80%, yet more preferably at least 90%, even more preferably at least 95% after storage for 4 months at 25 0 C. It is also preferred that the percentage recovery of said lipophilic anthracycline (such as valrubicin) is at least 80%, preferably at least 90%, more preferably at least 95%, even more preferably at least 98%, and yet even more preferably 99% after storage for 4 months at 25 0 C. It is furthermore preferred that the compositions are stable even after long term storage.
  • the percentage peak purity of the lipophilic anthracycline (such as valrubicin) comprised therein is at least 70%, more preferably at least 80%, yet more preferably at least 90%, after storage for 6 months at 25 0 C. It is also preferred that the percentage recovery of said lipophilic anthracycline (such as valrubicin) is at least 80%, preferably at least 90%, more preferably at least 95%, even more preferably at least 98%, and yet even more preferably 99% after storage for 6 months at 25 0 C. It is preferred that the pharmaceutical compositions according to the invention comprise one or more excipients in which the lipophilic anthracyclines of the invention are stable.
  • the pharmaceutical compositions of the invention comprises at least one polyether (also termed co-surfactant, see herein above), which is a polyether, wherein the percentage peak purity of a lipophilic anthracycline (such as valrubicin) comprised therein is at least 80%, preferably at least 85%, more preferably at least 90% after storage therein for 2 weeks at 25 0 C.
  • a polyether also termed co-surfactant, see herein above
  • the percentage peak purity of a lipophilic anthracycline (such as valrubicin) comprised therein is at least 80%, preferably at least 85%, more preferably at least 90% after storage therein for 2 weeks at 25 0 C.
  • compositions of the invention comprises at least one preservative, wherein the percentage peak purity of a lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic acid
  • anthracycline (such as valrubicin) comprised therein is at least 80%, preferably at least 85%, more preferably at least 90% after storage therein for 2 weeks at 25 0 C.
  • compositions according to the invention comprise solubilized lipophilic anthracycline. This may improve the ability of the lipophilic anthracycline to reach the target of disease.
  • the solubility of a lipophilic anthracycline according to the invention is preferably at least 0.5% w/w, yet more preferably at least 0.6% w/w, yet more preferably at least 0.7% w/w, yet more preferably at least 0.8% w/w, yet more preferably at least 0.9% w/w, yet more preferably at least 1 % w/w in the pharmaceutical composition according to the invention.
  • compositions according to the invention comprise one or more excipients in which the lipophilic anthracyclines of the invention are soluble.
  • the pharmaceutical compositions of the invention comprises at least one polyether (also termed co-surfactant, see herein above), wherein the solubility of a lipophilic anthracycline (preferably valrubicin) in said polyether is at least 5% w/w, preferably at least 10% w/w, even more preferably at least 20% w/w.
  • the pharmaceutical compositions of the invention comprises at least one preservative, wherein the solubility of a lipophilic anthracycline (preferably valrubicin) in said preservative is at least 5% w/w, preferably at least 10% w/w.
  • the present invention also provides pharmaceutical formulations comprising one or more colour masking agents, which in particular may be added to pharmaceutical formulations of the invention comprising a red lipophilic anthracycline.
  • pharmaceutical formulations for administration to the skin may comprise at least one colour masking agent.
  • the colour masking agent may in one embodiment be one or more dyes capable of masking red colour.
  • the colour masking agents are themselves dyes and preferably the pharmaceutical compositions may comprise:
  • the pharmaceutical composition will appear brownish and/or reddish.
  • the dyes may be any dye, preferably a dye which is not or only mildly irritant when applied to skin. Methods for determining whether a dye is irritant to skin are described herein below in the section "Skin irritation".
  • the green dye is selected from the group consisting of FD&C green No. 3, D&C green No. 5, D&C green No.6 and D&C green No.8.
  • the blue dye is selected from the group consisting of FD&C blue, (such as FD&C blue No. 1 ), D&C blue No. 4, FD&C blue No 2 and D&C blue No. 9.
  • the yellow dye is selected from the group consisting of FD&C yellow No 5, FD&C yellow No.
  • the at least one colour masking agent is selected from the group consisting of the colour masking agents FD&C blue and Sicovit Quinoline yellow.
  • the pharmaceutical compositions may be formulated in a number of different ways depending on the condition to be treated, the individual to be treated and the location of disease. Accordingly, the pharmaceutical composition is preferably formulated according to the need of the specific embodiment of the present invention.
  • the pharmaceutical composition may be in a form selected from the group consisting of vaginal cups, creams, ointments, gels, lotions, foams, pastes, sticks, patches, membranes, vaginal rings, vaginal tampons, vaginal strips, vaginal capsules, vaginal tablets, vaginal pessaries, suppositories, vaginal sponges, sprays, eye drops, and inhalators.
  • the pharmaceutical composition may be in a form selected from the group consisting of vaginal cups, creams, ointments, gels, lotions, foams, pastes, sticks, patches, membranes, vaginal rings, vaginal tampons, vaginal strips, vaginal capsules, vaginal tablets, vaginal pessaries, suppositories, vaginal sponges, sprays, eye drops, nasal drops and inhalators.
  • the pharmaceutical composition according to the present invention may preferably be a composition comprising a gel, an emulsified gel, an ointment, a cream, a foam, a solution or a lotion.
  • the pharmaceutical composition may furthermore preferably be in a form selected from the group consisting of a gel, an ointment, a cream, a foam, a solution or a lotion.
  • the pharmaceutical composition may more preferably be in a form selected from the group consisting of a gel, an ointment, a cream, a solution and a lotion.
  • compositions may be in the form of vaginal cups, patches, vaginal tampons, vaginal pessaries and/or vaginal sponges and may optionally comprise a gel, an ointment, a cream, a foam, a solution and/or a lotion comprising the lipophilic anthracycline, as described herein above.
  • the pharmaceutical composition may for example be in a form selected from the group consisting of vaginal cups, patches, vaginal rings, vaginal tampons, vaginal strips, vaginal capsules, vaginal tablets, vaginal pessaries, suppositories and vaginal sponges comprising said gel, ointment, cream, foam, solution or lotion.
  • the solution, gel, cream and/or ointment may be any of the gels, ointments, cremes, foams, solutions and/or lotions described herein above.
  • the pharmaceutical composition is in the form of a solution or cream or gel comprising said lipophilic anthracycline.
  • the pharmaceutical composition may further be in a form selected from the group consisting of patches, bandages, vaginal tampons, vaginal capsules, vaginal sponges, sprays, eye drops and inhalators comprising said solution.
  • patches, bandages, vaginal cups, patches, vaginal rings, vaginal tampons, vaginal strips, vaginal capsules, vaginal tablets, vaginal pessaries, suppositories and vaginal sponges may comprise a gel, foam, lotion, cream or ointment comprising a lipophilic anthracycline and a buffer with a pH of at the most 6 (i.e. any of the gels, foams, lotions, creams or ointments described herein in this section above).
  • Patches may take many different forms.
  • a patch comprises a polymer and an adhesive.
  • the lipophilic anthracycline may be deposited on the patch in the form of a solution, gel, cream and/or ointment.
  • the patch may be an occlusive patch.
  • the patch may be in the form of a thin membrane. This may in particular be the case for administration of lipophilic anthracycline to a mucosal membrane, for example for nasal administration, for administration to the mouth or for buccal administration, or for administration to the genital region.
  • Sticks as used herein may be any stick.
  • the stick will comprise a stiff formulation comprises a high amount of oil phase carrier allowing easy application of the formulation to a limited body surface area.
  • the stick may for example be a lipstick, or a stick useful for application to the skin or a mucosal membrane.
  • Pharmaceutical compositions containing an anthracycline according to the present invention may be prepared by conventional techniques, e.g. as described in Remington: The Science and Practice of Pharmacy 1995, edited by E. W. Martin, Mack Publishing Company, 19 th edition, Easton, Pa, unless otherwise described herein
  • Solutions, creams, ointments or gels according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base, such as known to the person skilled in the art.
  • the clinical condition to be treated according to the present invention is any clinical condition associated with hyperproliferation, i.e. cell hyperproliferation, preferably epithelial hyperproliferation and/or abnormal cell differentiation.
  • the clinical condition is associated with hyperproliferation of a local body area, preferably a local body area accessible without invasive means. More preferably, the clinical condition is associated with hyperproliferation of epithelial cells in skin and/or mucosal membranes.
  • the clinical condition is a clinical condition wherein hyperproliferation, such as e.g. epithelial hyperproliferation, epidermal hyperproliferation, hyperproliferation of keratinocytes, or dermal proliferation of small vessels; preferably epithelial hyperproliferation, epidermal hyperproliferation and hyperproliferation of keratinocytes; more preferably epithelial hyperproliferation or hyperproliferation of keratinocytes; even more preferably epithelial hyperproliferation; yet even more preferably epidermal hyperproliferation, is a primary factor of the pathogenesis.
  • hyperproliferation such as e.g. epithelial hyperproliferation, epidermal hyperproliferation, hyperproliferation of keratinocytes, or dermal proliferation of small vessels; preferably epithelial hyperproliferation, epidermal hyperproliferation and hyperproliferation of keratinocytes; more preferably epithelial hyperproliferation or hyperproliferation of keratinocyte
  • the condition may be associated with epidermal hyperproliferation and/or epidermal pre-neoplastic and/or neoplastic processes.
  • the clinical condition is a clinical condition wherein epidermal hyperproliferation is a primary factor of the pathogenesis. Hyperproliferation of epidermis may for example involve
  • condition according to the present invention may be selected from the group consisting of psoriasis, actinic keratosis, seborrheic keratosis, lichen planus (lichen ruber planus), basocellular carcinoma of the skin, squamous cellular carcinoma of the skin, planocellular carcinoma of the skin, verruca vulgaris, condyloma acuminata of skin or mucosal membranes, lichen sclerosis, cutaneous T-cell lymphomas, cutaneous metastasis, Karposi sarcoma and cicatricial hypertrophy.
  • condition according to the present invention may be selected from the group consisting of psoriasis, actinic keratosis, seborrheic keratosis, lichen planus
  • lichen ruber planus basocellular carcinoma of the skin, squamous cellular carcinoma of the skin or mucosal membranes, planocellular carcinoma of the skin, verruca vulgaris, condyloma acuminata of skin or mucosal membranes, lichen sclerosis, cutaneous T-cell lymphomas, cutaneous metastasis, Karposi sarcoma and cicatricial hypertrophy.
  • the clinical condition is cutaneous metastasis.
  • the primary tumour from which the metastasis is derived may be any tumour; for example the primary tumour may be breast cancer.
  • the clinical condition to be treated with lipophilic anthracyclines formulated as described by the pharmaceutical compositions of the present invention is a condition associated with hyperproliferation, preferably epidermal hyperproliferation, preferably a condition associated with psoriasis, and more preferably psoriasis vulgaris.
  • the condition to be treated is related to an epidermal hyperproliferation (e.g. psoriasis, skin cancer, basal cell carcinoma, malignant melanoma, cutaneous metastasis, hyperproliferating keratinocytes), and accordingly is located on the skin, then it may be preferred to use a pharmaceutical composition according to the present invention in the form of a water in oil emulsion.
  • psoriasis includes all types of psoriasis known to the person skilled in the art.
  • psoriasis may be selected from the group consisting of psoriasis vulgaris, guttate psoriasis, flexural psoriasis,
  • erythrodermic psoriasis generalised pustular psoriasis and localised pustular psoriasis, preferably psoriasis vulgaris, guttate psoriasis, flexural psoriasis, and localised pustular psoriasis.
  • psoriasis may be selected from the group consisting of psoriasis vulgaris, guttate psoriasis, flexural psoriasis, erythrodermic psoriasis, generalised pustular psoriasis and localised pustular psoriasis, preferably psoriasis vulgaris, guttate psoriasis, flexural psoriasis, nail psoriasis and localised pustular psoriasis.
  • the psoriasis to be treated according to the present invention may be mild, moderate, more severe or very severe psoriasis, such as psoriasis wherein less than 2 percent, for example 2% to 5%, such as 5% to 10%, for example 10% to 15%, such as more than 15% of the skin is affected.
  • the clinical condition is a clinical condition wherein hyperproliferation of mucosa, preferably hyperproliferation of epithelial cells of mucosa is a primary factor of the pathogenesis.
  • a pharmaceutical composition according to the present invention in the form of an emulsified gel or a gel, non-limiting example are the formulations described in examples 9, 10, and 16 herein.
  • the clinical conditions to be treated with lipophilic anthracyclines formulated as described in the pharmaceutical compositions of the present invention are neoplastic or preneoplastic conditions affecting the epithelium of the genitals, reproductive organs, lips, oral cavity, nasal cavity, pharynx, larynx, trachea, or bronchi, or affecting the eye.
  • the clinical conditions to be treated with lipophilic anthracyclines may be squamous cell carcinomas or cancers of the genitals, reproductive organs, the lower gastrointestinal tract and/or the eyes. More preferably the clinical conditions to be treated with lipophilic anthracyclines may be cancers of the genitals, reproductive organs, the lower gastrointestinal tract and/or the eyes.
  • the genitals may preferably be selected from the group consisting of penis, cervix, vagina and vulva.
  • the clinical condition may be neoplastic or preneoplastic conditions of the penis, preferably carcinoma of the penis (penile carcinoma), for example squamous cell carcinoma of the penis, such as squamous cell carcinoma originating in the glans or foreskin.
  • the clinical condition may also be condylomas of the penis.
  • the only effective treatment of penile cancer is surgery, optionally in combination with other treatments.
  • the present invention provides a non-invasive method for treating neoplastic or preneoplastic conditions of the penis by administering a lipophilic anthracycline to the penis, preferably locally to the affected site. More preferably said lipophilic anthracycline is administered in a pharmaceutical formulation according to the invention as described herein in the section "Pharmaceutical compositions" including the subsections of that section.
  • Very preferred formulations for administration to patients suffering from neoplastic or preneoplastic condition of the penis may be selected from the group consisting of patches, gels, creams or ointments. The formulations may be administered with or without occlusion, e.g. an occlusive bandage, plaster etc.
  • the clinical condition may also be neoplastic or preneoplastic conditions of the vulva, for example neoplastic or preneoplastic conditions such as vulvar intraepithelial neoplasia (VIN) or dysplasia of the labia majora or the labia minora.
  • the clinical condition may be vulvar cancer, for example squamous cell carcinoma originating from vulvar tissue, such as from the epithelium of vulvar tissue.
  • the vulvar cancer may also be basal cell carcinoma of the vulva.
  • the clinical condition may also be condylomas of the vulva. Currently, vulvar cancer is treated by surgery.
  • the present invention provides a non-invasive method for treating neoplastic or preneoplastic conditions of the vulva by administering a lipophilic anthracycline to the vulva, preferably locally to the affected site. More preferably said lipophilic anthracycline is administered in a pharmaceutical formulation according to the invention as described herein in the section "Pharmaceutical compositions" including the subsections of that section.
  • Very preferred formulations for administration to patients suffering from neoplastic or preneoplastic condition of the vulva may be selected from the group consisting of patches, sticks, gels, creams and ointments.
  • the clinical condition may also be neoplastic or preneoplastic conditions of the vagina, preferably vaginal cancer, for example carcinoma in situ or squamous cell carcinoma of the vagina.
  • the clinical condition may also be condylomas of the vagina, in particular of the areas surrounding the vaginal entrance.
  • the present invention provides a noninvasive method for treating neoplastic or preneoplastic conditions of the vagina by administering a lipophilic anthracycline to the vagina, preferably locally to the affected site. More preferably said lipophilic anthracycline is administered in a pharmaceutical formulation according to the invention as described herein in the section
  • compositions including the subsections of that section.
  • Very preferred formulations for administration to patients suffering from neoplastic or preneoplastic conditions of the vagina may be selected from the group consisting of vaginal cups, creams, gels, patches, vaginal rings, vaginal tampons, vaginal strips, vaginal capsules, vaginal tablets, vaginal pessaries and vaginal sponges.
  • the reproductive organs may preferably be selected from the groups consisting of uterus and the cervix, preferably the cervix.
  • the present invention provides a non-invasive method for treating cervical cancer by administering a lipophilic anthracycline to the cervix, preferably locally to the affected site. More preferably said lipophilic anthracycline is administered in a pharmaceutical formulation according to the invention as described herein in the section
  • “Pharmaceutical compositions” including the subsections of that section.
  • Very preferred formulations for administration to patients suffering from cervical intraepithelial neoplasia I to III may be selected from the group consisting of vaginal cups, creams, gels, emulsified gels, ointments, suppositories, patches, vaginal rings, vaginal tampons, vaginal strips, vaginal capsules, vaginal tablets, vaginal pessaries and vaginal sponges.
  • the lower gastrointestinal tract preferably comprises or more preferably consists of the part of the lower gastrointestinal tract which is readily accessible by non-invasive means.
  • the clinical condition may be a neoplastic or preneoplastic condition of the anus or the perianal area.
  • the clinical condition may thus for example be polyps of the anus or perianal area, condylomas of the anus or perianal area, anal cancer or perianal cancer.
  • Said anal cancer or perianal cancer may for example be a squamous cell carcinoma or a basal cell carcinoma
  • the present invention provides a non-invasive method for treating neoplastic or preneoplastic condition of the anus or the perianal area by administering a lipophilic anthracycline to the anus or perianal area, preferably locally to the affected site. More preferably said lipophilic anthracycline is administered in a pharmaceutical formulation according to the invention as described herein in the section "Pharmaceutical compositions" including the subsections of that section.
  • Very preferred formulations for administration to patients suffering from neoplastic or preneoplastic condition of the anus or the perianal area may be selected from the group consisting of suppositories, patches, gels, emulsified gels, sticks, creams and ointments.
  • the clinical condition according to the present invention may also be a neoplastic or preneoplastic condition of the eyes, such as papillomas of the eye or cancers of the eye.
  • the eye includes the globe, the orbit and the adnexal structures.
  • the clinical condition may for example be orbital, , basal cell carcinoma of the eyelid, conjunctival squamous cell carcinoma of the eye, ,medulloepithelioma,.
  • the present invention provides a non-invasive method for treating neoplastic or preneoplastic condition of the eye by administering a lipophilic anthracycline to the eye, preferably locally to the affected site. More preferably said lipophilic anthracycline is administered in a pharmaceutical formulation according to the invention as described herein in the section "Pharmaceutical compositions" including the subsections of that section.
  • Very preferred formulations for administration to patients suffering from neoplastic or preneoplastic condition of the eye may be selected from the group consisting of eye drops and eye ointments.
  • the clinical condition is a neoplastic or
  • the upper airway tract comprises and more preferably consists of the lips, nasal cavity, the oral cavity, larynx, pharynx, bronchi and trachea.
  • the clinical condition may for example be a cancer of the upper airway tract or papillomas of the upper airway tract.
  • the clinical condition may for example be a cancer of the lips, cancer of the nasal cavity, cancer of the oral cavity, cancer of the tongue and/or cancer on the vocal cords.
  • Papillomas of the upper airway tract may for example be Laryngeal papillomatosis.
  • the clinical condition may also be erythroplakia, leukoplakia, carcinoma in situ in the mouth.
  • the lipophilic anthracycline is administered in a pharmaceutical formulation according to the invention as described herein in the section
  • compositions including the subsections of that section.
  • Very preferred formulations for administration to patients suffering from neoplastic or preneoplastic condition of the upper airway tract may be selected from the group consisting of ointments, sprays, and patches; additionally, these may be selected from the group consisting of ointments, sprays, sticks, and patches.
  • “Pharmaceutical compositions” including the subsections of that section) may be a clinical condition associated with or preferably caused by infection with human papilloma virus (HPV).
  • HPV human papilloma virus
  • the clinical condition may for example be papillomas, such as condylomas.
  • the present invention specifically relates to the use of the pharmaceutical compositions of the invention for treatment of a neoplastic or preneoplastic condition affecting the epithelium of genitals, reproductive organs, lips, oral cavity, nasal cavity, pharynx, larynx, trachea, or bronchi, or affecting the eye.
  • the neoplastic or preneoplastic condition may furthermore be a condition associated with an infection with Human Papilloma virus (HPV) and/or it may be a neoplastic or preneoplastic condition selected from the group consisting of vulva squamous cell carcinoma, cervical cancer, vaginal cancer, penis cancer, perianal cancer, anogenital cancer and squamous cell carcinoma of the nasal cavity, lips, oral cavity, the pharynx, the larynx, the trachea, the bronchi or the eye.
  • HPV Human Papilloma virus
  • the neoplastic or preneoplastic condition to be treated with the pharmaceutical compositions of the invention is a condition associated with an infection with Human Papilloma virus (HPV) and/or it is a carcinoma in situ or a squamous cell carcinoma selected from the group consisting of cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN), squamous cell carcinoma in situ (Bowens disease), squamous cell carcinoma of vagina, penile squamous cell carcinoma, perianal squamous cell carcinoma, squamous cell carcinoma of the nasal cavity, squamous cell carcinoma of the oral cavity, squamous cell carcinoma of the lips, squamous cell carcinoma of the pharynx, squamous cell carcinoma of the larynx, squamous cell carcinoma of the trachea, squamous cell carcinoma of the bronchi, and squamm
  • the neoplastic or preneoplastic condition to be treated with the pharmaceutical compositions of the invention is a condition associated with an infection with Human Papilloma virus (HPV) and/or it is a carcinoma in situ or a squamous cell carcinoma selected from the group consisting of cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN), squamous cell carcinoma in situ (Bowens disease), squamous cell carcinoma of vagina, penile squamous cell carcinoma, and perianal squamous cell carcinoma.
  • CIN cervical intraepithelial neoplasia
  • VIN vulvar intraepithelial neoplasia
  • Bowens disease squamous cell carcinoma of vagina
  • penile squamous cell carcinoma and perianal squamous cell carcinoma.
  • neoplastic or preneoplastic condition may be condylomas on the genitals or reproductive organs.
  • a specific aspect of the present invention relates to the use of a pharmaceutical composition comprising a lipophilic anthracycline (as defined herein) formulated for local administration for treatment of a neoplastic or preneoplastic condition affecting the epithelium of genitals, reproductive organs, perianal region, lips, nasal cavity, pharynx, larynx, trachea, or bronchi, or affecting the eye.
  • the neoplastic or preneoplastic condition may furthermore be a condition associated with an infection with Human Papilloma virus (HPV) and/or it may be a neoplastic or preneoplastic condition selected from the group consisting of vulvacarcinoma, cervical cancer, vaginal cancer, penis cancer, perianal cancer, anogenital cancer and squamous cell carcinoma of the nasal cavity, the pharynx, the larynx, the trachea, the bronchi or the eye.
  • HPV Human Papilloma virus
  • the neoplastic or preneoplastic condition to be treated is a condition associated with an infection with Human Papilloma virus (HPV) and/or it is a carcinoma in situ or a squamous cell carcinoma selected from the group consisting of cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN), squamous cell carcinoma in situ (Bowens disease), squamous cell carcinoma of vagina, penile squamous cell carcinoma, perianal squamous cell carcinoma, squamous cell carcinoma of the nasal cavity, squamous cell carcinoma of the lips, squamous cell carcinoma of the pharynx, squamous cell carcinoma of the larynx, squamous cell carcinoma of the trachea, squamous cell carcinoma of the bronchi, and squamous cell carcinoma of the eye.
  • CIN cervical intraepithelial neop
  • the neoplastic or preneoplastic condition is a condition associated with an infection with Human
  • Papilloma virus and/or it is a carcinoma in situ or a squamous cell carcinoma selected from the group consisting of cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN), squamous cell carcinoma in situ (Bowens disease), squamous cell carcinoma of vagina, penile squamous cell carcinoma, and perianal squamous cell carcinoma.
  • the neoplastic or preneoplastic condition may be condylomas on the genitals or reproductive organs.
  • the present invention furthermore relates to a method of treating a condition associated with hyperproliferation, such as e.g. epithelial hyperproliferation, epidermal hyperproliferation, hyperproliferation of keratin ocytes, or dermal proliferation of small vessels; preferably epithelial hyperproliferation, epidermal hyperproliferation and hyperproliferation of keratinocytes; more preferably epithelial hyperproliferation or hyperproliferation of keratinocytes; even more preferably epithelial hyperproliferation; yet even more preferably epidermal hyperproliferation in an individual in need thereof comprising administering topically to said individual a pharmaceutical composition comprising
  • a condition associated with hyperproliferation such as e.g. epithelial hyperproliferation, epidermal hyperproliferation, hyperproliferation of keratin ocytes, or dermal proliferation of small vessels; preferably epithelial hyperproliferation, epidermal hyperproliferation and hyperproliferation of keratinocyte
  • composition further comprises an aqueous phase comprising at least one buffering system having a pH from pH 2.2 to pH 6, and wherein the water content of the pharmaceutical composition is less than 30%. Further details relating to this method may be found herein in the sections relating to the pharmaceutical
  • composition the clinical conditions, administration forms, combination therapy, and skin irritation.
  • the present invention furthermore relates to a method of treating a condition associated with hyperproliferation, such as e.g. epithelial hyperproliferation, epidermal hyperproliferation, hyperproliferation of keratinocytes, or dermal proliferation of small vessels; preferably epithelial hyperproliferation, epidermal hyperproliferation and hyperproliferation of keratinocytes; more preferably epithelial hyperproliferation or hyperproliferation of keratinocytes; even more preferably epithelial hyperproliferation; yet even more preferably epidermal hyperproliferation in an individual in need thereof comprising administering topically to said individual a pharmaceutical composition comprising a lipophilic anthracycline formulated for local administration.
  • a condition associated with hyperproliferation such as e.g. epithelial hyperproliferation, epidermal hyperproliferation, hyperproliferation of keratinocytes, or dermal proliferation of small vessels; preferably epithelial hyperproliferation, epidermal
  • condition to be treated may be a neoplastic or preneoplastic condition affecting the epithelium of genitals, reproductive organs, nasal cavity, pharynx, larynx, trachea, or bronchi, or affecting the eye.
  • the neoplastic or preneoplastic condition may furthermore be a condition associated with an infection with Human Papilloma virus (HPV) and/or it may be a neoplastic or preneoplastic condition selected from the group consisting of vulva carcinoma, cervical cancer, vaginal cancer, penis cancer, perianal cancer, anogenital cancer and squamous cell carcinoma of the nasal cavity, the pharynx, the larynx, the trachea, the bronchi or the eye.
  • HPV Human Papilloma virus
  • the neoplastic or preneoplastic condition is a condition associated with an infection with Human Papilloma virus (HPV) and/or it is a carcinoma in situ or a squamous cell carcinoma selected from the group consisting of cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN), squamous cell carcinoma in situ (Bowens disease), squamous cell carcinoma of vagina, penile squamous cell carcinoma, perianal squamous cell carcinoma, squamous cell carcinoma of the nasal cavity, squamous cell carcinoma of the lips, squamous cell carcinoma of the pharynx, squamous cell carcinoma of the larynx, squamous cell carcinoma of the trachea, squamous cell carcinoma of the bronchi, and squamous cell carcinoma of the eye.
  • CIN cervical intraepithelial neoplasia
  • Papilloma virus and/or it is a carcinoma in situ or a squamous cell carcinoma selected from the group consisting of cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN), squamous cell carcinoma in situ (Bowens disease), squamous cell carcinoma of vagina, penile squamous cell carcinoma, and perianal squamous cell carcinoma.
  • the neoplastic or preneoplastic condition may be condylomas on the genitals or reproductive organs.
  • the individual to be treated according to the present invention is preferably an individual suffering from a condition associated with hyperproliferation, for example epithelial hyperproliferation.
  • the individual may be any animal, however, preferably the individual is a mammal, more preferably a human being.
  • the treatment may be ameliorating treatment and/or the treatment may be curative treatment and/or the treatment may be prophylactic treatment.
  • the treatment may abolish or relieve some or all of the symptoms of the condition during treatment and/or for a specific period of time after cessation of treatment, but then one or more symptoms may reappear.
  • the symptoms may reappear about 1 day, such as about 2 days, for example about 3 days, such as about 3 to 5 days, for example about 5 to 7 days, such as about 7 to 10 days, for example about 10 to 15 days, such as about 15 to 20 days, for example about 20 to 30 days, such as about 30 to 60 days, for example about 60 to 120 days, such as more than 120 days after cessation of treatment.
  • the pharmaceutical formulations according to the present invention are preferably formulated for local administration, such as e.g. to the skin, to an epithelial surface, to the mucosa of e.g. the nasal cavity etc., accordingly, it is preferred to administer the formulations/compositions topically.
  • Topical administration according to the present invention should be understood as local administration directly to the site of disease.
  • topical administration results in that the majority of the active compound, i.e. anthracycline, is not systemically absorbed and hence substantially only capable of exerting its effect locally at the site of application.
  • systemic absorption is less than 10%, such as less than 8%, for example less than 6%, such as less than 5% for example less than 4%, such as less than 3%, for example less than 2%, such as less than 1%.
  • Even more preferably systemic uptake is less than 10 ng/ml, more preferably less than 5 ng/ml, even more preferably less than 1 ng/ml as measured in blood of a patient receiving treatment.
  • administration of the pharmaceutical compositions according to the present invention does not result in any severe malaise or any severe irritation, more preferably administration does not result in any significant nuisance to the individual to be treated, most preferably, administration does result in only mild and/or no malaise, irritation and/or nuisance.
  • Administration frequency will depend on the particular clinical condition to be treated and the particular formulation of the pharmaceutical composition.
  • the pharmaceutical composition as described herein is formulation for administration once or twice daily, preferably once daily.
  • compositions according to the present invention may comprise one or more different active components in addition to the anthracycline.
  • the pharmaceutical composition furthermore comprises a second active component.
  • the second active component may be any active
  • the second active component is selected from the group of active components, which are known to be active against the condition to be treated. Accordingly, when the condition is psoriasis, the second active component may be a component which is known in the art to be effective against psoriasis.
  • the second active component may be selected from the group consisting of steroids, vitamin-D analogues, vitamin- A analogues, vitamin D, vitamin A, calcineurin inhibitors, salicylic acid, methotrexate, and cyclosporine, anthraline and coal tar.
  • the methods of treatment disclosed by the present invention may also be combined with one or more second treatments.
  • the second treatment may be treatment with a different anthracycline, so that the method comprises treatment with 2, for example 3, such as 4, for example 5, such as more than 5 different anthracyclines.
  • the second treatment according to the present invention may also be treatment which is not administration of an anthracycline.
  • the second treatment(s) may be selected from the group of treatments, which are known to be active against the condition to be treated.
  • the second treatment when the condition is psoriasis the second treatment may be a treatment, which is known in the art to be effective against psoriasis, when the condition is e.g. a cancer disease the second treatment may be an anticancer treatment.
  • the second treatment may be selected from the group consisting of treatment with sunlight, ultraviolet light B (UVB) or PUVA.
  • the anthracycline according to the present invention may sensitise the individual towards treatment with sunlight, ultraviolet light B (UVB) or PUVA, in a manner such as lower amount of light and/or irradiation is required to obtain the desired effect.
  • the second treatment may be administration of at least one compound selected from the group consisting of steroids, coal tar, vitamin-D analogues, vitamin D, vitamin A analogous, vitamin A, anthralin, calcineurin inhibitors, salicylic acid, methotrexate, and cyclosporin.
  • the second treatment may furthermore be a treatment with biologies, such as e.g., adalimumab, etanercept or infliximab (TNF- ⁇ inhibitors), Ustekinumab (IL12/23 inhibitor) and others.
  • the anthracycline and the second treatment may be administered simultaneously or sequentially in any order.
  • the treatments are administered in a rotational manner, such as one treatment is administered for a specific predetermined amount of time, after which the second treatment is administered for a specific predetermined amount of time, after which the first treatment is administered again and so forth.
  • Rotational treatment may also comprise more than 2, such as 3, for example 4, such as 5, for example more than 5 different treatments.
  • the pharmaceutical compositions according to the invention are not or only mildly irritant when applied to skin of a subject.
  • the lipophilic anthracyclines and other compounds (such as dyes or buffering agents) comprised in the pharmaceutical compositions according to the invention are not or only mildly irritant when applied to skin or mucosa of a subject.
  • irritation is determined by visual assessment by an observer
  • a score of skin irritation is provided on a scale from 0 to 9
  • the visual assessment is preferably carried out by one or more trained observer(s).
  • a score of 0 on such a scale indicates that the pharmaceutical formulation or the anthracycline is not irritant
  • a score of in the range of 1 to 3 on such a scale indicates that the pharmaceutical formulation or the anthracycline is mildly irritant.
  • the assessment is made in the range of 23 to 76 hours after application of the pharmaceutical formulation or the anthracycline onto the skin of said subject, more preferably in the range of 23 to 48 hours after application of the pharmaceutical formulation or the anthracycline or other compound onto the skin of said subject.
  • the subject may be any mammal, for example mini pigs, preferably the subject is a human being.
  • the scale used is as follows:
  • the composition when applied to skin has a score for skin irritation of at the most 3 on a scale from 0 to 9, wherein 0 is no reaction and 9 is the strongest reaction.
  • skin irritation is determined as described in Basketter et al., Contact Dermatitis, 1997, 37:218-220.
  • skin irritation may be determined by a standard human 4-h patch test as described in D. A. Basketter et al, Contact Dermatitis, 2004, 51 :1-4: "Determination of skin irritation potential in the human 4-h patch test". The assessment of the skin reaction is graded as follows:
  • the pharmaceutical compositions according to the present invention is preferably not, or only mildly irritant when applied to skin, as corresponding to a grading of 0 or + on the human 4-h patch scale.
  • the pharmaceutical compositions, when applied to skin has a grading in the human 4-h patch test of at the most +, on a scale from 0 to +++, wherein 0 is no reaction and +++ is the strongest reaction. Examples
  • Anthracyclines incl. Valrubicin, decreases cell proliferation in vitro
  • DJM-1 , HSC-1 , two human skin Squamous Cell Carcinoma cell lines, HaCaT cell lines, (human spontaneously transformed normal keratinocytes) were cultured for 24h and 48h in the presence of Valrubicin, AD41 and Doxorubicin in increasing concentrations as indicated ( ⁇ g/ml).
  • Cells were propagated in DMEM (Gibco) with addition of 10% Fetal Bovine Serum (Gibco) and a cocktail of antibiotics: Penicillin, Streptomycin, and Gentamycin
  • the final concentration of acetone in the cell culture medium was of 0.01 %, thus the control medium for these two drugs contained the same acetone concentration. It has been previously shown that this acetone concentration did not affect cell proliferation.
  • Doxorubicin was used as a water solution, thus its control culture was grown in medium alone.
  • Valrubicin 24 h From left to right: Valrubicin 24 h; Valrubicin 48 h; AD41 24 h; AD41 48 h; Doxorubicin 24 hr; Doxorubicin 48 hr.
  • Figure 1 B shows the dose response effect expressed as % proliferation of HSC-1 cells against increasing amount of compounds. From left to right: Valrubicin 24 h; Valrubicin 48 h; AD41 24 h; AD41 48 h; Doxorubicin 24 hr; Doxorubicin 48 hr.
  • Figure 1 C shows the dose response effect expressed as % proliferation of HaCaT cells against increasing amount of compounds. From left to right: Valrubicin 24 h;
  • Skin cancer is induced in BALB/6J mice by a two step treatment with DMBA and TPA.
  • DMBA creates mutations in the skin cells and TPA stimulates growths of these cells. Some of the formed papillomas will become malignant (SCC). This DMBA/TPA skin cancer model is used worldwide. The BALB/6J is used instead of C57BL/6J due to a reported increased formation of papillomas (More, 1999).
  • Lactic acid - sodium lactate buffers pH 2.5, 100 mM were prepared by preparing two primary solutions.
  • a 0.2 M solution of lactic acid was prepared by weighing 1.8 g of lactic acid into a 100 ml volumetric flask, and making up to volume with deionised water.
  • a 0.2 M solution of sodium lactate was prepared by weighing 2.24 g of sodium lactate in a 100 ml volumetric flask and making up to volume with deionised water.
  • the Lactic acid - sodium lactate buffer, pH 2.5 was prepared by adding 60 ml of the 0.2 M solution of lactic acid and 40 ml of the 0.2 M sodium lactate solution to a 200 ml volumetric flask and making up to volume with deionised water. The pH of the solution was determined and either reduced using 0.2 M lactic acid solution or increased using 0.1 M sodium lactate.
  • the coloured solutions were prepared by weighing 0.00875 g and 0.10625 g of FD & C blue and D&C yellow into a suitably sized container, to the container was added approximately 49.885 g of the pH 2.5 lactic acid - sodium lactate buffer.
  • the water soluble excipients were weighed into a suitably sized container (aqueous phase) and the oil soluble ingredients were weighed into a separate suitably sized container (oil phase).
  • Valrubicin was dissolved in phenoxyethanol prior to addition of the remaining aqueous phase (where applicable).
  • the oil phase excipients were heated at approximately 65 ° C in a temperature controlled water bath until all excipients had melted.
  • the aqueous phase was heated until it had reached approximately 65 ° C.
  • the aqueous phase was added very slowly to the oil phase while the oil phase was stirred vigorously.
  • the emulsion was then homogenised using a Silverson homogeniser for 1 - 2 min.
  • the formulation was stirred by hand using a spatula until the temperature of the formulation had reached approximately ambient temperature.
  • the pH of the final composition was measured to approximately pH 4.7 - 4.8.
  • Glycine - HCI buffer pH 2.5, 100 mM were prepared by preparing two primary solutions.
  • a 0.2 M solution of HCL was prepared by weighing 4 g of 1 M HCI into a 20 ml volumetric flask, and making up to volume with deionised water.
  • a 0.2 M solution of glycine was prepared by weighing 0.75 g glycine in a 50 ml volumetric flask and making up to volume with deionised water.
  • the glycine - HCI buffer, pH 2.5 was prepared by adding 15 ml of the 0.2 M solution of HCI and 50 ml of the 0.2 M glycine solution to a 100 ml volumetric flask and making up to volume with deionised water.
  • the pH of the solution was determined and was either reduced with 0.1 M HCI or increased using 0.1 M glycine if required.
  • the coloured solutions were prepared by weighing 0.00875 g and 0.10625 g of FD & C blue and D&C yellow into a suitably sized container, to the container was added approximately 49.885 g of the pH 2.5 Glycine-HCI buffer.
  • the pH of the final composition was measured to approximately pH 4.1 - 4.2.
  • the formulation was prepared as described in example 4.
  • the pH of the final composition was measured to approximately pH 4.4 - 4.6.
  • the formulation was prepared as described in example 5.
  • the pH of the final composition was measured to approximately pH 4 4.
  • Keratome biopsies were taken from distinct psoriatic donors and transported to the animal facility (0 0 C). Each series represent one donor. The following day, the keratomes are cut in smaller pieces before transplantation on the back of anesthetized SCID mice (6-8 weeks old).
  • mice Valrubicin cream (VLD32 as described in Example 4)
  • Group 2 of 2 mice Vehicle cream (Same as VLD32 as described in Example 4, but lacking Valrubicin)
  • mice Betamethasone valerate
  • Subjective assessment of psoriasis resolution was determined using a 4-point semi-quantitative clinical psoriasis score (redness, scaling and thickness of the skin) with a range from 0 to 3, wherein 3 is severe, and 0 is no psoriasis.
  • Valrubicin cream VLD32
  • the cream vehicle without active ingredient was being tested.
  • valrubicin cream was compared with conventional topical psoriasis treatments, namely Calcipotriol and Betamethasone valerate which were included as positive controls in all 5 series. All treatment groups were compared to an untreated group confirming psoriasis presence at the end of the 3 weeks.
  • FIGS. 4A-F are showing the results of all 5 series.
  • VLD32 denoted “Valrubicin” in the figure
  • 3 and 4 treatment with VLD32 was significantly better than treatment with either Calcipotriol or Betamethasone valerate after 21 days.
  • Treatment with VLD32 was significantly more effective that treatment with vehicle cream without Valrubicin in all 5 series.
  • Valrubicin in formulation A(content as described in Example 15) was tested in the psoriasis xenograft transplantation model, where human psoriasis plaque skin was transplanted onto SCID mice maintaining the characteristics of psoriasis.
  • mice engrafted with psoriatic plaque skin were divided into four treatment groups: vehicle cream (formulation A without valrubicin), untreated, valrubicin cream (formulation A), and clobetasol propionate (the strongest corticosteroid approved for topical treatment for psoriasis). All treatments were applied once daily to the human grafted skin in the psoriasis xenograft transplantation model for twelve days using the semi-quantitative clinical psoriasis 4-point score with a range from 0 to 3 as described above.
  • the semi-quantitative clinical psoriasis score was significantly reduced after 12 days treatment in the valrubicin group (Formulation A) (1.7 ⁇ 0.1 ; mean ⁇ SEM, p ⁇ 0.01 ) compared to the vehicle group (2.2 ⁇ 0.1 ;mean ⁇ SEM), indicating remission of psoriasis.
  • the semi-quantitative clinical psoriasis score in the clobetasol propionate treated group(positive control) was reduced to 1.5 ⁇ 0.1 (mean ⁇ SEM).
  • Example 9
  • the formulation was prepared as described in example 16, except for the buffer which was prepared as follows:
  • the pH 4.5 lactate buffer was prepared by preparing two primary solutions.
  • a 0.1 M solution of lactic acid was prepared by weighing 0.9 g of lactic acid into a 100 ml volumetric flask, and making up to volume with deionised water.
  • a 0.1 M solution of sodium lactate was prepared by weighing 1.12 g of sodium lactate in a 100 ml volumetric flask and making up to volume with deionised water.
  • the lactate buffer pH 4.5
  • the lactate buffer pH 4.5
  • the pH of the solution was determined and adjusted if required.
  • a coloured buffer solution was prepared by weighing 0.04375 g and 0.53125 g of FD & C blue and D&C yellow into a suitably sized container, to the container was added approximately 49.425 g of the pH 4.5 lactic acid buffer. The pH of the final composition was measured to approximately pH 6.4.
  • the formulation was prepared as described in example 8, and in example 9 (with regard to the buffer).
  • the content of Valrubicin was determined by extracting the compound from the formulation and determining the concentration. The extraction procedure used was dependant on the formulation type (W/O or Emulgel) and the target was to have approximately 100 mg/ml Valrubicin in the samples analysed by HPLC. Extraction of Valrubicin from W/O formulations (VLD32).
  • a sample (approximately 1 ml) of the supernatant was transferred to a glass HPLC vial and analysed by HPLC.
  • approximately 100 mg of emulsified gel 4 containing 1 % Valrubicin was accurately weighed into a 10 ml volumetric flask.
  • the volumetric flask was made up to volume with acetonitrile and the flask vortex mixed for 1 min to disperse the gel.
  • the volumetric flask was stirred for approximately 4 h at ambient temperature.
  • the percentage recovery of Valrubicin from the formulations at the 1 month and 3 months time points were considered acceptable (Table 1A).
  • the percentage recovery of Valrubicin from the formulations from the longer term (6, 9 and 12 months) time points was likewise considered acceptable (Table 1 B). For the 12 months time point are both data for glass and High Density Polyethylene (HDPE) containers.
  • HDPE High Density Polyethylene
  • solvents also termed oil phase carriers, solubilizers and co-surfactants herein elsewhere
  • solubility studies where performed.
  • the solvents in which valrubicin showed high solubility were ethanol, benzyl alcohol, PEG 400, glycofurarol, phenoxyethanol and Transcutol.
  • the solubility of valrubicin was observed to be low ( ⁇ 0.2 %) in cyclomethicone, glycerol, IPP, IPM and water.
  • solvents also termed oil phase carriers, solubilizers and co-surfactants herein elsewhere
  • solvents also termed oil phase carriers, solubilizers and co-surfactants herein elsewhere
  • Valrubicin was observed to remain stable (100% peak purity) in Lauroglycol® 90, benzyl alcohol, Crodamol GTCC and phenoxyethanol at 25 and 40 ° C for two weeks. No additional peaks were observed at 25 ° C in 50% ethanol in pH 4 buffer. At the four week time point, Valrubicin was observed to be stable (peak purity of 100%) after storage in Crodamol GTCC, benzyl alcohol and phenoxyethanol.
  • Valrubicin The peak purity of Valrubicin was observed to decrease with higher pH, whereby significant loss of Valrubicin peak purity was observed at pH 5 and above. Valrubicin also showed a decrease in peak purity after storage in PEG 400, Propylene glycol, Transcutol® P, ethanol and Arlasolve DMI.
  • Example 15 Based on the above results, the formulations of Example 15 were prepared. Example 15
  • JH12 valrubicin dissolved in castor oil, Panthenol, Lameform, propylene glycol, lactic acid, Dehymuls LE: 2 g was dissolved in 54%, 4.2%.
  • the formulations were prepared by first preparing the oil phase and the water phase separately.
  • the oil phase was prepared by dissolving valrubicin and then mixing said mixture with the rest of the constituents of the oil phase.
  • the water phase was prepared by dissolving all substituent of the water phase in the water. Finally, the water-in-oil formulation was prepared by mixing the water phase into the oil phase.
  • Formulation A JH32
  • the pH of formulation A has been measured to approximately pH 3.7.
  • EMULSIFIED GEL 4A with valrubicin and emulsified gel 4P which is the formulation without active ingredient.
  • the buffer and the coloured solution were prepared as described in example 4.
  • Valrubicin was weighed into a suitably sized container and dissolved in phenoxyethanol and ethanol prior to the addition of Transcutol® P, propylene glycol, alpha tocopherol, ascorbyl palmitate and EDTA disodium. The solution was stirred until Valrubicin and the anti-oxidants had dissolved, prior to addition of the gelling agent (HPC HF). The gels were allowed to hydrate for a minimum of 3 h at ambient temperature. The
  • Crodamol GTCC and Cremophor RH40 were weighed into a suitably sized
  • the pH of the final composition was measured to approximately pH 4.3 - 4.6.
  • VLD32 - 1.0% w/w valrubicin (see Example 4 for content of VLD32) • VLD43 - 0.5% w/w valrubicin (see Example 5 for content of VLD42)
  • Emulsified gel 4A Emulsified gel 4A
  • Emulsified gel 5A Emulsified gel 5A
  • receiver fluid 200 ⁇ l was removed from the receiver compartment of each Franz cell via the sampling arm after 2, 4, 6, 8, 24, 30 and 48 h and analysed via HPLC.
  • valrubicin was recovered and analysed via HPLC from the following components:
  • the amount of valrubicin recovered from the stratum corneum after application of VLD32 was significantly higher (p> 0.005 using Bonferroni correction) than all other formulations applied to the intact human epidermal membrane.
  • the amount of valrubicin recovered from the stratum corneum was approximately 2.3 and 1.2 ⁇ g from the cells applied with Emulsified gel 4 and Emulsified gel 5.
  • Table 6 shows the amount of Valrubicin recovered from the epidermal membrane (EM) 48 h after application of Valrubicin containing formulations to the intact and perturbed human epidermal membrane. In addition the amount of Valrubicin recovered from the stratum corneum 48 h after application of valrubicin containing formulations to the intact human epidermal membrane is indicated.
  • CaSki (cervix SCC, HPV16), SW756 (cervix SCC HPV18), and SW954 (vulva SCC) cells from human cell lines were cultured in the presence of vehicle, valrubicin, or doxorubicin.
  • Valrubicin and doxorubicin were added in increasing concentrations: 0.02 ug/ml, 0.04 ug/ml, 0.08 ug/ml, 0.16 ug/ml, 0.32 ug/ml and 0.64 ug/ml.
  • the CellTiter-Glo® viability assay kit (Promega, USA) was employed to assess the effect of valrubicin and doxorubicin on cell proliferation.
  • Figures 5A-C show that valrubicin and doxorubicin have a significant dose-dependant anti-proliferative effect on CaSki cells (cervix SCC, HPV16) after 48- and 72 hrs of stimulation. After 72 hrs of stimulation with valrubicin, cell viability was reduced to ⁇ 50% upon stimulation with the highest concentration. Doxorubicin demonstrates a greater anti-proliferative effect than valrubicin at the 48- and 72 hrs assessments.
  • Figures 5D-F show that valrubicin and doxorubicin have a significant dose-dependant anti-proliferative effect on SW756 cells (cervix SCC, HPV18) after 48- and 72 hrs of stimulation. After 72 hrs of stimulation with valrubicin, cell viability was reduced to ⁇ 50% upon stimulation with the highest concentration. Doxorubicin demonstrates a greater anti-proliferative effect than valrubicin at the 48- and 72 hrs assessments.
  • Figures 5G-I show that valrubicin and doxorubicin have a significant dose-dependant anti-proliferative effect on SW954cells (vulva SCC) after 48- and 72 hrs of stimulation. After 72 hrs of stimulation with valrubicin, cell viability was reduced to 25% upon stimulation with the highest concentration. Doxorubicin demonstrates a greater antiproliferative effect than valrubicin at the 48- and 72 hr. assessments.
  • Valrubicin and doxorubin demonstrate a significant dose-dependant anti-proliferative effect on human CaSki cells (cervix SCC, HPV16), SW756 cells (cervix SCC, HPV18) and SW954cells (vulva SCC) after 48-and 72 hr stimulation.
  • Valrubicin demonstrates a consistent dose-dependant reduction of cell viability in all the human SCC cell lines investigated after 48- and 72 hrs of stimulation with the greatest effect, expressed as reduction of cell viability, to 25% at the highest concentration in the SW954 cells (vulva SCC) which indicates that valrubicin may be attractive for topical use in said conditions, currently treated with surgical intervention as first line therapy.
  • doxorubicin demonstrated a higher reduction in cell viability confirming results in previous studies.
  • doxorubicin is extremely toxic to tissue and skin upon extravasations, it can not be considered for topical treatment of said conditions.
  • the experiment was performed using normal and abraded abdominal human skin. To simulate damaged skin, the skin sample was stripped ten times with Tape film (19 mm wide) to partially remove the Stratum Corneum before insertion into the Franz diffusion cells. Individually calibrated Franz cells (FZ) with a diffusion area and acceptor volume of approximately 3 cm 2 and 20 ml, respectively, was employed to determine the penetration of valrubicin. The receptor compartment was filled with acceptor fluid. Each formulation (30 mg +/- 5%) was applied to the diffusion skin area and homogenously spread on the skin surface using a spatula. The application was followed by massaging simulating the real application conditions. The Franz diffusion cells were covered by Parafilm® during the 24 hour period.
  • the remaining valrubicin content in the residual formulation in the donor skin was determined by HPCL for each FZ.
  • the formulation remaining on the skin surface was collected with cotton swabs with aid of extraction medium (ACN/water 60:40 v/v %) and transferred into glass tubes with an extraction medium.
  • the concentration of the test substance in the skin samples was quantified.
  • Two segmenting techniques: tape stripping and cryosectioning, were applied to separate different skin layers parallel to the upper surface of the sample and thus provide information on the extent to which the test compound had penetrated into the different skin areas.
  • the upper epidermal layers of the skin were stripped off using Tape film. In total 18 tape strips was performed per each skin biopsy of the intact skin and 8 tape strips for the damaged skin.
  • receiver fluid was removed from the receiver compartment of each Franz cell via the sampling arm after 24h and analysed via HPLC.
  • valrubicin was recovered and analysed via HPLC from the following components:
  • Figure 6 shows the results for intact skin, and is a comparison of Valrubicin amount [ ⁇ g/cm 2 ] found in the 2 first tape-strips (2TS), 16 tape-strips (Stratum Corneum, 16TS), deeper skin layers (residual skin after stripping) and acceptor medium from the formulations A (JH32) and VDL32.
  • the drug amount measured after 24 hours for the samples after 6 times stripping was approximately 3-fold higher for the formulation VDL32 (0.32 +/- 0.05 mg/cm 2 ) in comparison to the Formulation A (0.1 1 +/- 0.02 mg/cm 2 ).
  • the measured drug amount in the deeper skin layers was also clearly higher for VDL32 (0.08 +/- 0.06 mg/cm 2 ) in comparison to Formula (0.01 +/- 0.01 mg/cm 2 ).
  • No Valrubicin could be detected in the acceptor medium during the experiment with damaged skin.
  • Figure 7 shows the results for damaged skin, and is a comparison of Valrubicin amount [ ⁇ g/cm 2 ] found in the 2 first tape-strips (2TS), 6 tape-strips (Residual Stratum Corneum, 6TS), deeper skin layers (residual skin after stripping) and acceptor medium from the formulations Formulation A (JH32) and VDL32.
  • the experiment was performed using pre-menopausal human cervical tissue from 2 donors. Individually calibrated Franz cells with a diffusion area and acceptor volume of approximately 0,14 cm2 and 5,5 ml, respectively, was employed to determine the penetration of valrubicin. The receptor compartment was filled with acceptor fluid. The formulation, approximately 30 mg, was pipetted onto the surface of the tissue and left there for 24 hours.
  • the residual formulation was removed by rinsing twice with extraction medium (2 x 100 ⁇ l_) and the concentration of the test substance was quantified. Acceptor medium samples were also collected.
  • cryosection was used as segmenting technique to separate different tissue layers parallel to the upper surface of the sample and thus provide information on the extent to which the test compound had penetrated into the tissue. The tissue was frozen at - 20 0 C before cryosegmentation. After segmenting all samples were extracted with ACN/water 60:40 (v/v %) and quantified by LC-UV.
  • the results show that the drug substantially remains in the tissue surface, hereby indicating that the formulation is suitable for local application and treatment of localized conditions, e.g. cervical hyperproliferative conditions such as pre-neoplasia, carcinoma in situ.
  • the drug amount penetrated was 2.03 ⁇ 0.13 mg which corresponds to 0.66 ⁇ 0.55 % of the total drug amount applied.
  • the drug substance quantified in the deeper segments was 0.19 ⁇ 0.06 % of the total amount applied.
  • Figure 8 shows the penetration of Valrubicin into cervical tissue after 24-hour incubation with emulsified gel 4, valrubicin 1%.
  • the diagram shows the concentration profile in the tissue.
  • the results from the second experiment employing donor tissue 2 have confirmed the findings from the first experiment employing donor tissue 1.
  • Valrubicin was mostly concentrated in the tissue surface (1.45 DO.95 Dg which corresponds to 0.48 DO.32 % of the total drug amount applied) after the incubation time of 24 hours, whereas the drug substance quantified in the deeper segments (segment 1 , segment 2 , segment 3 and deeper tissue or rest) was 0.17 DO.12 % of the total amount applied.
  • the values from the mass balance were within the limits recommended by the SSPC 2006 Guideline for the in vitro dermal absorption (100 D 15%).
  • Figure 9 shows the penetration of Valrubicin into cervical tissue after 24-hour incubation with emulsified 4 gel valrubicin 1 %.
  • the diagram shows the concentration profile in the tissue.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des préparations pharmaceutiques stables comprenant une anthracycline lipophile solubilisée et l'utilisation de ces préparations pour le traitement de troubles cliniques, dans lesquels l'hyperprolifération, telle que l'hyperprolifération épithéliale est un facteur principal de la pathogénie. Les compositions pharmaceutiques comprennent i) une anthracyclique lipophile; ii) un ou plusieurs excipients à phase huileuse; iii) un ou plusieurs agents de solubilisation pharmaceutiquement acceptables; iv) un ou plusieurs co-tensioactifs. La composition comprend également une phase aqueuse comprenant au moins un système tampon présentant un pH compris entre environ 2.2 et environ 6, la teneur en eau de la composition pharmaceutique étant inférieure à 30%.
EP10734023A 2009-07-17 2010-07-08 Traitement de troubles hyperprolifératifs Withdrawn EP2456423A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200900874 2009-07-17
PCT/DK2010/050179 WO2011006504A2 (fr) 2009-07-17 2010-07-08 Traitement de troubles hyperprolifératifs

Publications (1)

Publication Number Publication Date
EP2456423A2 true EP2456423A2 (fr) 2012-05-30

Family

ID=42629337

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10734023A Withdrawn EP2456423A2 (fr) 2009-07-17 2010-07-08 Traitement de troubles hyperprolifératifs

Country Status (2)

Country Link
EP (1) EP2456423A2 (fr)
WO (1) WO2011006504A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013026454A1 (fr) 2011-08-22 2013-02-28 Valderm Aps Traitement d'états cliniques avec des anthracyclines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4610977A (en) 1985-04-08 1986-09-09 The University Of Tennessee Research Corporation N-alkyl and N-benzyl adriamycin derivatives
EP1423126B1 (fr) 2001-08-14 2007-08-29 Valderm APS Traitement d'etats hyperproliferatifs des surfaces corporelles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2011006504A2 *

Also Published As

Publication number Publication date
WO2011006504A3 (fr) 2011-10-20
WO2011006504A2 (fr) 2011-01-20

Similar Documents

Publication Publication Date Title
US10137140B2 (en) Therapeutic composition
US10722493B2 (en) Methods for treating fibroproliferative disorders in a mammal
RU2560677C2 (ru) Кожная композиция, включающая аналог витамина d и смесь растворителя и поверхностно-активных веществ
CN107921013A (zh) 双醋瑞因或大黄酸局部用制剂及其用途
AU2008331500B2 (en) Intravesical compositions with valrubicin for the treatment of bladder cancer
US20190224145A1 (en) Use of Adelmidrol in the Treatment of Epithelial Dysfunctions
US8263567B2 (en) Treatment of hyperproliferative conditions of body surfaces
WO2011006504A2 (fr) Traitement de troubles hyperprolifératifs
JP2021508334A (ja) 男性型禿頭症を含む皮膚障害を処置するための局所製剤
CN113543773B (zh) 稳定的局部用非诺多泮组合物
US20060204474A1 (en) Treatment of epithelial layer lesions
AU2002320964A1 (en) Treatment of hyperproliferative conditions of body surfaces
US20080132534A1 (en) Pharmaceutical composition comprising a macrolide immunomodulator
JPS6327432A (ja) 高増殖性上皮疾患の治療のための局部的なメトトレキセ−ト調製物およびそれを用いた高増殖性上皮疾患の治療方法
AU2004226822B2 (en) Pharmaceutical composition comprising a macrolide immunomodulator
AU2006200822B2 (en) Treatment of epithelial layer lesions
WO2014076642A1 (fr) Composition topique pour l'administration par voie transépidermique ou transdermique de paracétamol

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120323

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20130322

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130802